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Comments on the cover illustration 
The illustrations depict several important milestones in urinalysis. 
The painting (from Jan Jozef Horemans, “Graviditas ominosa uroscopia”) describes the 
Medieval art of ‘piss-pot science’ showing the uroscopist examining urine in a matula. 
The bottles represent several possible states and colours of urine from which the uroscopist 
could deduce the subject’s disease. 
The technical drawing illustrates the construction of a modern flow cytometer, while the 
graph represents a calibration curve of modern urine test strips. 
 
  
 
The most exciting phrase to hear in science, 
the one that heralds new discoveries, 
is not “Eureka!” but 
“That's funny...” 
ISAAC ASIMOV 
 
 
 
 
Only two things are infinite: 
the universe and human stupidity; 
and I'm not sure about the former 
ALBERT EINSTEIN 
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Introduction 
— 
From uroscopy to urinalysis 
 
 
  
 
   
CHAPTER 1: Introduction - From uroscopy to urinalysis 
History of urinalysis 
References (1) and (2) deal with this paragraph. 
Macroscopic examination of urine for diagnostic, therapeutic and prognostic purposes is as 
old as medicine itself. Egyptians already could diagnose a diabetic’s urine by observing the 
attraction of flies by urine spilled on the ground. Until the end of the 17th century, urine 
samples were examined in their natural condition. 
Kidney and urinary tract diseases have always fascinated mankind. Early attention to this 
specific field of medicine was paid by Hippocrates. By his ideas, the interior was ruled by 
a constant flow of all kinds of fluids: blood, mucus, urine, bile, feces, etc. Thus, the body’s 
secretions were of crucial importance. They were instruments for the perception of the 
interior while great stress was laid on argument by analogy. 
All these ideas were theoretically framed by the doctrine of the four humours which 
dominated medical thinking for over 2000 years preserving the humoral pathology idea far 
into the 19th century. 
As a tool and diagnostic aid for physicians, uroscopy originated in antique roots, reaching 
its heights during the Middle Ages. Special attention was focused on the meaning that was 
attributed to the colour of the urine. Hence, already early on coloured note-boards or 
urinary glass panes with up to 20 colour grades arranged in columns or circles as 
mnemonic aids could be found. The colour of the urine indicated the state of the humours 
in the veins: “Like blood, like urine”. 
Not only colour was important in uroscopy, early (macroscopic) sediment analysis took 
into account the consistency and the position of the sediment in interpreting diseases. 
 
Finally, uroscopy became the province of quacks, charlatans and piss-prophets. It revived 
in the 18th century and regained credibility in the 19th and the first half of the 20th century 
in parallel with advances in biochemistry. The impressive state of knowledge developed 
over centuries lost its validity overnight when a modern scientific approach began around 
1850 with the quantitative chemical analysis of urine, the introduction of microscopy and 
later on test strip analysis and flow cytometry. 
More than hundred years after introduction of qualitative chemical tests in combination 
with microscopic analysis of urine, urinalysis is challenged by new medical needs as well 
as technical developments and advances in scientific knowledge. 
   
Test strip analysis 
The revolutionary transition of uroscopy to a more scientific medical discipline took place 
in the 19th century and is linked to names such as Berzelius, Heller, Scherer and Liebig. 
They mark the birth of clinical chemistry with classical urine analyses for substances such 
as protein, sugar, bile acids and hemoglobin (3). 
These were originally wet chemistry tests that were not always easy to perform since a 
substantial amount of time and equipment was needed. Hence, the search for some form of 
convenient chemistry testing was started early leading first to the development of tablets 
and later to specific strips. The principle of test strips can be dated back to the invention of 
litmus paper by Boyle (approximately 1670) or even to the Roman Plinius who described a 
test for iron by means of papyrus strips soaked in gallae which was later used for human 
urine. The advantages of the technique of test strips are obvious: it is practicable for 
general practitioners and even self-testing can be an option. 
The modern era of the urine test strip as we know it today started around 1956 (4;5) 
followed by the instrument reading of test strips in the 1970’s. Nowadays, also very 
sensitive test strips exist or immunological techniques have been introduced for the 
determination of specific proteins (e.g. albumin, alpha 1-microglobulin (A1M)) (6;7). 
 
From urine microscopy to flow cytometry 
The realisation that examination of urine by microscopy could provide vital information 
occurred only from the 16th century onwards evolving finally into a routine practice, due to 
improvement of the optics system, in the 19th century. Rayer and Vigla then emphasized 
the concept that the results of microscopic investigation should always be associated with 
chemical analysis. This was the period of major breakthroughs concerning the relation 
between urinary particles and disease (8). 
However, urinary microscopy has numerous drawbacks related to centrifugation, optics 
and staining possibly leading to poor visualisation of some urinary formed elements. Other 
techniques can overcome these problems e.g. phase contrast microscopy, supravital 
staining and polarized light microscopy, but in general microscopy has some major 
drawbacks being an imprecise and laborious technique with a high interobserver 
variability. These problems have led to the widely used “sieve concept”, which states that 
if the results of chemical screening with dipsticks are negative, then microscopic 
   
examination is unnecessary. Such simplification, however, may lead to substantial losses in 
diagnostic yield. 
Therefore, several attempts have been made to develop automated and more standardized 
methods to improve both the accuracy and the productivity of urine sediment analysis. The 
first device occurred in the eighties with the Yellow IRIS (9;10) that captures pictures of 
native urine on a video camera. Offering a better precision and sensitivity than visual 
microscopy, throughput was affected by particle concentration and user classification, 
whereas sensitivity of detection and original particle differentiation depended on the used 
instrumental algorithm. Moreover, it required continuous monitoring of images by the 
operator and did not have walkaway capability, necessitating the continuous presence of a 
system-operator. The advantage of a walkaway analyzer is that it handles the samples 
totally independent once it is started so no more actions are expected from the user, which 
is of importance in the ever increasing lab automation. The UA-1000 and UA-2000 
(Sysmex Corporation, Kobe, Japan), based on the same principle, were introduced in the 
early nineties. They still suffered from low throughput and required a trained analyst to 
assess the images. To face the demands for a fully automated high throughput analyzer, the 
Sysmex UF-100 was developed based on a different concept. This analyzer is a flow 
cytometer designed to automate the recognition and counting of particles in urine. It 
classifies particles based on fluorescent intensity (cells are stained with 2 fluorescent dyes), 
electrical impedance, and forward angle light scatter. 
New automated analyzers have evolved out of this same principle like the UF-50 and 
Bacsys. The UF-50 is a smaller version of the UF-100 for lower throughput while the 
Bacsys is a dedicated instrument for use in the microbiological screening of urine and other 
human body fluids. It quantifies both bacteria and leukocytes based on fluorescence 
flowcytometry using a proprietary fluorescence polymethine dye which is excited by a red 
semi-conductor laser (11-13). This laser has a lower operating cost than the one used in the 
previous versions. 
Meanwhile, an improved version of the IRIS, the Iris iQ200 Automated Urine Microscopy 
Analyzer (Iris Diagnostics, USA), also based on imaging technology using a video camera 
and strobe lamp to detect and sort particles based on predetermined particle dimensions, 
was developed and is gaining use in routine clinical laboratories (14). It disposes of a 
neural network to improve categorization of the urinary particles. An extra advantage of 
this system compared to others is its mechanic, not only software-based, coupling with an 
automated dipstick reading device. 
   
The greatest contribution of both concepts is the improved precision and sample 
throughput compared with manual microscopy. 
 
Specific tubular proteins in urinalysis 
References (15-25) deal with this paragraph. 
As with electrophoresis, quantitative analysis of urine marker proteins has been 
successfully applied to detect and differentiate nephrological and urological disorders. 
These microproteins are not only tools to non-invasive early detection of renal 
abnormalities, whilst their purpose usually is to locate the source of the proteinuria or 
hematuria. 
Traditionally, total protein and albumin were measured but now also other proteins can be 
helpful in diagnosing urinary tract disease. 
For evaluation of the glomerular function, IgG and alpha 2-macroglobulin can be used. To 
assess the tubular (dys)function, A1M, beta 2-microglobulin, retinol binding protein, Clara 
cell protein and N-acetyl-beta-D-glucosaminidase are available of which the first three are 
mostly available in dedicated laboratories. Not all these analytes are equally fit to be used 
in routine clinical practice: problems may exist concerning their stability in urine (beta 2-
microglobulin) or availability of routine assays (retinol binding protein, N-acetyl-beta-D-
glucosaminidase). Everaert et al. showed A1M to be useful in the detection of renal tubular 
damage in patients with outflow disease of the upper tract and to be diagnostic for vesico-
ureteral reflux (VUR). 
Most important reasons for selecting A1M in our studies are the combination of its stability 
in human urine ex vivo together with the availability of easy and automated test kits 
(especially on a routine turbidimetric device such as a Modular P, Roche Diagnostics, 
Mannheim, Germany) allowing it to be introduced in a routine clinical laboratory. 
 
Expert systems 
The general framework of the routine clinical laboratory of the early 21st century is 
characterized by an increasing integration of different techniques on one platform e.g. 
chemistry and immunochemistry. Furthermore, since routine clinical laboratories are 
confronted with a growing complexity of diagnostic tests, an increased workload, stringent 
laboratory accreditation demanding increasing standardisation, continuous shortening of 
turn-around-time and budget restrictions, the introduction of artificial intelligence by 
   
means of expert systems has gained an important place in the automation process to meet 
these demands. 
In this view, it seemed logical to combine data in urinalysis gathered by different 
techniques but from the same sample since both techniques used (flow cytometry and test 
strip analysis) have different methodological pitfalls inherent to the method. In 1999, 
Langlois et al (21) developed a rule-based expert system that performs a cross-check of 
flow cytometric data (UF-100) with results obtained by semi-quantitative dipstick testing 
allowing a clinically acceptable sieving system to reduce the workload of microscopic 
sediment urinalysis. The current use of this system in our laboratory and a short description 
is explained in more detail in chapter 3. 
By using knowledge based expert systems, expert knowledge can improve the information 
obtained from urine analysis. Professor W. Guder and co-workers elaborated a Urine 
Protein Expert System (UPES) based on a basic set of urinary proteins and a test strip 
screening (26-31). It was successfully integrated and evaluated to support clinical 
diagnosis showing that non-invasive urine protein differentiation may be a useful 
diagnostic strategy in nephrology. The multivariate evaluation of the excretion pattern 
allows differentiation of prerenal from glomerular, tubular, and postrenal causes of 
proteinuria and hematuria. 
This system combines a rule-based pattern definition database with implemented logical 
and mathematical algorithms. The interpretative text covers not only underlying kidney 
disorders but also comments on preanalytical and analytical problems. 
 
Expert systems are not a privilege of urinalysis alone. Also for enzyme electrophoresis 
such as for amylase and alkaline phosphatise, expert systems have been developed (32). 
These systems combine the data from the specimen analysis and data covering patient 
characteristics like age and sex featuring a bidirectional link with the Laboratory 
Information System (LIS). The software then produces a report that can be communicated 
to the clinician to support the interpretation and to suggest possible work-outs. 
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CHAPTER 2: Outlines and aims 
 
Despite the older view that urinalysis is not the most exciting and dynamic area in clinical 
laboratory medicine and that it is sometimes being regarded as an ancient, non-evolving 
technique, improvements are still ongoing and are more than necessary. 
Urinalysis always has been a cumbersome, time-consuming technique subject to great 
inter-operator variability. The first, not completely successful, attempt to automate urine 
microscopy was based on photographic capturing techniques (UA-1000 and UA-2000 from 
Sysmex Corporation, Kobe, Japan; Yellow IRIS from Iris Diagnostics, Chatsworth, USA). 
More recent developments of automated techniques comprise urinary flow cytometry (UF-
100, UF-50 and Bacsys; Sysmex, Japan) and automated urine microscopy readers (IQ200, 
Iris Diagnostics, Chatsworth, USA) introducing a faster and much more refined and 
standardized technique in this cumbersome field. Inter-observer variance rates dropped 
dramatically while sample throughput rose significantly. 
In our laboratory, most experience is gained regarding the application of the UF-100 in a 
routine clinical laboratory setting. Certain pitfalls exist in using this technique: yeasts can 
be counted as RBC, extreme pH conditions can destroy some brittle urinary formed 
elements like casts, etc. So it was a first logical step to combine flow cytometric data with 
urinary test strip results to overcome some of the weaknesses of both techniques. In 1999, 
Langlois et al. implemented this practice in such an expert system (21). 
However, as automated test strip readers, which were developed much earlier than flow 
cytometry, reported semi-quantitative data, there was an imbalance of the quality of the 
obtained data being quantitative on one hand (flow cytometry) and ordinal scaled data on 
the other hand (test strip readers). With the newer test strip readers, quantitative reflectance 
data are available to the user. We were interested in the quality of these data in order to 
integrate them in an improved expert system. 
Before the availability of fingerprick (skin puncture) tests, urine test strips were also used 
to monitor diabetics as a warning for imminent diabetic ketoacidosis (DKA). With 
fingerprick tests being available, this application of urine test strips is obsolete but other 
problems arise in specific patient groups. For diabetics treated with an insulin infusion 
pump, monitoring of acetoacetate (AcAc) and 3-hydroxybutyrate (3HB) after an episode of 
DKA is of clinical importance. Commercial test strips are available for monitoring blood 
3HB but these strips are expensive. We investigated the possible use of urine test strips in 
this setting. 
  
Standard urinary test strips can only measure AcAc and not 3HB. Using a specific sample 
pre-treatment we were able to measure both AcAc and 3HB and applied this technique in 
this specific setting. 
 
In a routine clinical laboratory, other body fluids with expected low cell counts are 
investigated, such as cerebrospinal fluid and peritoneal dialysis fluid from continuous 
ambulatory peritoneal dialysis (CAPD). The presence of a low number of cells, as found in 
urine, makes it logical to investigate the usability of a urinary flow cytometer for these 
samples. Van Acker et al. (33) already described their experience with investigating 
cerebrospinal fluid using this technique. Later on, Aps et al. applied it to saliva (34) and 
Muylaert et al evaluated it for sperm counting (35). We investigated the possible use and 
pitfalls of using a urine flow cytometer in case of CAPD-fluid. 
 
Specific proteins play an important role in evaluating urinary tract disease and expert 
systems, like UPES developed by Professor Guder and Dr. Ivandic, can provide 
nephrological diagnoses based on specific urinary protein analysis (28;29). 
Specifically A1M seems to be an interesting protein given its stability in a broad urinary 
pH-range and the availability of convenient automated assays. The most important 
drawback at the time being is its lack in standardisation. After a literature search, we 
evaluated whether several possible ratios based on A1M and data from test strip and flow 
cytometric analysis would be of assistance in the evaluation of urological and renal 
conditions. 
 
Main goal 
The main goal of this thesis was to explore the possibilities of the available state-of-the-art 
automated urinalysis techniques in a routine laboratory setting, to expand their use in 
clinical and laboratory practice, and to improve the diagnostic possibilities by combining 
the information obtained by these individual techniques. 
 
Specific aims 
• To investigate the possible advantage of quantitative urine strip analysis compared to 
the routinely used semi-quantitative reporting. 
• The possible use of quantitative test strip reading in a clinical setting of diabetic patients 
  
treated with insulin pumps. 
• The application of urine flow cytometry in other body fluids with low cell counts 
especially peritoneal dialysis fluid. 
• Combining the information provided by flow cytometry, test strips and specific urinary 
proteins for use in diagnosis and monitoring urological and nephrological disease. 
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CHAPTER 3: Application of test strips and alpha 1-
microglobulin in urinalysis 
 
This chapter covers the chemical principles handled in this thesis. 
Chapters 3A (Quantitative evaluation of urinalysis test strips) and 3B (Quantitative 
measurements of ketone bodies in urine using reflectometry) handle about specific 
applications of urinary test strips. Chapter 3C (Alpha 1-microglobulin: clinical laboratory 
aspects and applications) contains a review about A1M, in preparation of the investigation 
about combining information from different techniques (flow cytometry, proteins and 
dipstick) to diagnose urinary tract disorders which is covered further on. 
 
Present situation in the laboratory of Clinical Biology at Ghent 
University 
The standard operating procedure for urine microscopy and test strip analysis in our 
laboratory consists of the combined use of a UF-100 flow cytometer (Sysmex, Kobe, 
Japan) and a test strip reader (one Urisys 2400 and one Miditron; Roche Diagnostics, 
Mannheim, Germany). In the ideal case, every sample is presented first to one of the test 
strip readers followed by flow cytometric analysis. The two instruments are linked by 
software that compares the results of both analysers and, on the basis of a set of rules 
compiled in an expert system, it produces a print-out of the samples and parameters that 
should be re-investigated by a trained laboratory technician. For example, high RBC and 
WBC counts raise flags on the UF-100 screen to review the specimen under a microscope. 
However, when UF-100 RBC and WBC data are concordant with dipstick hemoglobin and 
leukocyte esterase reactions, there would be no need for additional microscopic 
confirmation. 
Remarks are also reported (e.g. old sample?, Proteus?, Myoglobunuria?, Sterile pyuria?, 
Hyaline casts?, Pathological casts?, Total number>250000, Protein, Hematuria?, Casts are 
unstable in alkaline urine). 
The operator only checks and corrects the parameters indicated. After re-analysis is 
completed, the reviewed results together with the remarks are transmitted to the LIS to be 
reported to the physician. 
 
 Urine test strip reading: instrument description 
The classical test strip is read a certain time after dipping in urine with the help of the 
ambient light. This, of course, is very subjective and user dependent since the brightness of 
the light differs and the time after reading is not fixed. 
To standardize this process automated test strip readers (reflectometers) have been 
developed that work based on the principle of reflectomety in which a standardized light 
source (usually a LED) is used and the percent reflectance is measured. The intensity of the 
reaction colour of the test pad is detected by measuring the percentage of light reflected 
from the surface of the test pad. The higher the analyte, the higher the colour intensity and, 
thus, the lower the reflectance. The reflectance value, expressed as a percentage within a 
range from 100% (white) to 0% (black), is therefore inversely related to the concentration 
of the analyte in the sample. 
 
 
Figure 1: the relation between analyte concentration and % reflectance 
 
Despite these originally quantitative results, until recently it was common practice to 
express results as ordinal scaled (normal, negative, positive, 0, +, ++, etc.). With the latest 
generation of test strip readers it is possible to obtain the quantitative reflectance data for 
all of the classically used test pads: leukocyte esterase, nitrite, protein, glucose, ketones, 
urobilinogen, bilirubin, hemoglobin/myoglobin, and pH. 
 
The automated reader used in our studies was the URISYS 2400 (Roche, Germany). It 
measures the usual analytes as described above while specific gravity (refractometry 
based) and clarity are measured in a flow cell and colour is rated with a specific algorithm 
against the blank pad on the test strip. The reflectance data can be downloaded or 
forwarded to linked PC’s. 
It is this instrument that we evaluated in the first study presented in chapter 3A 
(Quantitative evaluation of urinalysis test strips) by comparing it with validated 
 
  
biochemistry methods. It was our intent to investigate the possible added value and the 
analytical performance of the originally quantitative reflectance data. 
 
Ketone bodies and diabetic ketoacidosis (DKA) 
Low concentrations of ketone bodies are always found in the blood and urine of a healthy 
reference population. This can be explained by the fact that ketones are a primary source of 
energy for some organs and a secondary or alternate source for others. Three ketone bodies 
exist: 3HB, AcAc and acetone of which 3HB and AcAc are the most important ones. 
Acetone, the least abundant ketone body, is eliminated primarily through respiration 
causing the characteristic ‘‘pear-drop’’ smell present in DKA. 
 
In response to certain stresses or in various medical conditions, ketone body levels rise in 
both blood and urine. This is of particular interest in diabetics who are much more 
vulnerable for metabolic imbalance, possibly leading to DKA. The objective of routine 
ketone monitoring, especially of 3HB and AcAc, is to detect and thus prevent DKA. 
The American Diabetes Association recommends that anyone with diabetes performs 
urinary tests for ketones during times of illness or stress, during pregnancy, when blood 
glucose levels of 17 mmol/L persist, or whenever symptoms of ketoacidosis are observed. 
The presence of precipitating factors that contribute to the development of DKA would 
also indicate that ketones should be monitored. While diabetes type 1 patients are at 
particular risk, ketoacidosis is increasingly recognized as a problem associated with type 2 
patients as well, especially those who are insulin-dependent. 
To diabetics treated with an insulin infusion pump, monitoring of AcAc and 3HB is of 
clinical importance to reduce the misdiagnosis of DKA (e.g., due to undetected leakage of 
the infusion system, infection, mismanagement of the infusion pump). 
In DKA, the ratio of 3HB to AcAc increases from 1:1 to as much as 5:1 making 3HB the 
most important ketone body to monitor in this situation. 
When acidosis resolves with treatment, 3HB is oxidized to AcAc, returning the ratio to 
baseline conditions. 
 
Classically, the nitroprusside reaction on urine test strips (Ketostix, Acetest) has been used 
to carry out semi-quantitative assays of urinary ketones. A drawback of this method is that 
it mainly measures AcAc. The presence of ketone bodies in urine at concentrations 
detectable by strips has long been recognized as a symptom of DKA. However, since 
  
AcAc is measured semi-quantitatively and the nitroprusside reaction reacts weakly with 
acetone and does not register the presence of 3HB, this technique has limited value in 
judging DKA. When 3HB is the only ketone present, which can occur occasionally, the 
colour reaction underestimates the magnitude of ketoacidosis. 
Moreover, when the acidosis is resolved by treatment, AcAc levels remain high due to the 
oxidation of 3HB. When using urine test strips, this may lead to the wrong impression that 
ketosis is not improving. 
 
Since 3-HB is the major ketone body in DKA, the monitoring of AcAc may not be 
clinically important at all, or may be misleading. Nowadays, an expensive 3HB assay can 
be used on a handheld sensor (Optium meter; Medisense/Abbott, Abingdon, UK) to 
measure this ketone body using blood from a fingerprick test. 
However, compared to the traditional nitroprusside reaction on urine test strips, an accurate 
quantitative assessment of all ketone bodies in urine could provide a much more valuable 
insight in determining current metabolic status and treatment strategy. We evaluated the 
possibility to use urine test strips for this purpose. Therefore it was necessary to first 
develop a workaround for the specificity of the ketone test pad for AcAc. After a technical 
evaluation, samples were measured for AcAc and 3HB with the urine test strips and a 
validated routine chemistry method (chapter 3B: Quantitative measurements of ketone 
bodies in urine using reflectometry). 
 
Alpha 1-microglobulin (A1M) 
The evaluation of renal tubular function is an important issue in clinical laboratory 
medicine. Detection of urinary microproteins can help to detect renal abnormalities at an 
early stage and differentiate the various forms of renal and urological pathology by less 
invasive techniques. Several markers exist but the stable microprotein A1M, also called 
protein HC, is one of the most interesting ones due to its stability. 
We first made a round-up of the existing information of this protein so we could possibly 
use this in a second stage for diagnosing urological and nephrological diseases. Recent 
peer-reviewed literature was systematically checked until November 2003. Our findings 
were pooled and presented such that it can be used in the clinical laboratory (chapter 3C: 
Alpha 1-microglobulin: clinical laboratory aspects and applications). 
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Quantitative Evaluation of Urinalysis Test Strips
Joris Penders, Tom Fiers, and Joris R. Delanghe*
Background: Urine test strip results are generally re-
ported in categories (i.e., ordinal scaled), but automated
strip readers are now available that can report quantita-
tive data. We investigated the possible use of these
meters to complement flow cytometry of urine and
compared reflectance readings with quantitative deter-
minations of urinary glucose and microalbumin.
Methods: We compared URISYS 2400 (Roche) quantita-
tive reflectance data with data from the UF-100 (Sysmex)
and biochemical data for 436 nonpathologic and patho-
logic urine samples.
Results: Reproducibility of the reflectance signal was
good for high- and low-concentration urine pools for
protein (0.8% and 0.9% and 1.5% and 2.2% within and
between runs, respectively), leukocyte esterase (1.1%
and 1.0%; 5.1% and 1.2%), hemoglobin (1.7% and 1.1%;
8.9% and 1.1%) and glucose (2.1% and 0.5%; 6.5% and
2.3%). Fair agreement was obtained between UF-100 and
test strip reflectance data for erythrocytes and hemoglo-
bin (r  0.680) and leukocytes and leukocyte esterase
(r  0.688). Higher correlations were observed for
biochemical and test strip data comparing protein and
albumin (r  0.825) and glucose data (r  0.851). The
lower limits of detection for erythrocytes and leukocytes
were 8  106/L and 19  106/L, respectively. The protein
test (n  220) detected 86% (95% confidence interval,
78–92%) of samples with <30 mg/L albumin with a
specificity of 84% (95% confidence interval, 76–91%).
Conclusions: In urine test strip analysis, quantitative
hemoglobin and leukocyte esterase reflectance data are
complementary with flow cytometric results and glu-
cose and albumin results.
© 2002 American Association for Clinical Chemistry
Test strip analysis plays an important role in urinalysis as
such, and the value of test strip urinalysis as a screening
method has been thoroughly demonstrated (1 ). The re-
producibility of (semi)automated readings is at least as
good as visual readings (2 ), but most authors find the
analytical, clinical, and labor cost-saving advantages of
(semi)automated vs visual reading to be obvious (3 ).
Recently, the URISYS 2400 automated urine test strip
analyzer (Roche Diagnostics) was introduced. This instru-
ment offers the possibility to obtain reflectance readings.
Test results, therefore, no longer need to be expressed in
an ordinal scale. Access to the instrument’s raw data
theoretically allows a higher analytical sensitivity for
several analytes. Because microalbuminuria is generally
regarded as an excellent marker for assessing early renal
damage in common conditions such as diabetes and
hypertension (4–7) and as an early predictor of pre-
eclampsia during pregnancy (8 ), the availability of highly
sensitive test strip readers opens interesting perspectives
for assessing this phenomenon.
Flow cytometry has been introduced for urinalysis
(9, 10) to obtain quantitative data on urinary particles.
The imprecision of urinary flow cytometry is far less than
that of conventional urinary microscopy, but in some
cases urinary flow cytometry reports erroneous results
because of analytical interferences (e.g., calcium carbonate
crystals falsely increase erythrocyte counts; confusion
between yeast cells and erythrocytes). Langlois et al. (11 )
reported disagreement in erythrocyte counts between the
UF-100 and the hemoglobin test strip reaction in 6.5% of
cases. Of course, the frequency of erroneous results de-
pends on the proportion of pathologic samples and on the
preanalytical handling of samples. Combining diagnostic
information provided by urinary flow cytometry and
more quantitative test strip analysis therefore offers a
theoretical basis for the development of diagnostic expert
systems (11, 12).
In this study, we wanted to investigate the perfor-
mance of quantitative urinary test strip analysis. In par-
ticular, we wanted to compare the reflectance readings of
the protein test field with immunochemical microalbumin
determinations. We also wanted to explore the possibili-
ties of combining the two novel methods, particularly in
the analysis of erythrocytes, leukocytes, and glucose,
which are of major clinical importance.
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Materials and Methods
patients and samples
We studied 436 freshly collected urine samples submitted
to our routine laboratory for diagnostic urinalysis. All
samples were completely processed within 2–4 h after
arrival. Test strip urinalysis was carried out before flow
cytometry analysis (Sysmex UF-100; TOA Medical Elec-
tronics), using URISYS strips on a URISYS 2400 analyzer
(Roche Diagnostics). Combur 10-Test M strips on a Mid-
itron automated reflectance photometer (Roche) (13, 14),
used in our routine laboratory, were used in parallel as a
control. The strips include reagent pads for ordinal scale
reporting of relative density, pH, leukocyte esterase, ni-
trite, protein, glucose, ketones, urobilinogen, bilirubin,
and hemoglobin/myoglobin.
Day-to-day imprecision was assessed with control ma-
terial: Liquichek Urinalysis Control Levels 1 and 2 (Bio-
Rad). This is stable for 30 days when stored tightly capped
at 2–8 °C.
urinary flow cytometry
The Sysmex UF-100 is a urinary flow cytometer-based
walkaway instrument that performs automated micro-
scopic analysis. It has been extensively evaluated for
urinalysis (9–11, 15) as well as for cerebrospinal fluid
analysis (16 ). The principle is based on argon laser flow
cytometry. The UF-100 measures the conductivity and
categorizes the particles on the basis of their shape, size,
volume, and staining characteristics. The results are dis-
played in scattergrams, histograms, and as counts per
microliter as well as counts per high-power field. The
UF-100 automatically detects and counts red blood cells
(RBCs), white blood cells (WBCs), bacteria, yeast cells,
crystals, epithelial cells, small round cells, sperm cells,
and casts. Particles that cannot be classified in one of the
former categories are counted as “other cells”.
urisys 2400
Urine test strip analysis was performed with the auto-
mated URISYS 2400. These test strips are the same as used
in the Miditron but are supplied in a cassette holding 400
test strips for leukocyte esterase, nitrite, protein, glucose,
ketones, urobilinogen, bilirubin, hemoglobin/myoglobin,
and pH.
The intensity of the reaction color of the test pad is
detected by measuring the percentage of light reflected
from the surface of the test pad. The higher the analyte,
the higher the color intensity and, thus, the lower the
reflectance. The reflectance value, expressed as a percent-
age within a range from 100% (white) to 0% (black), is
therefore inversely related to the concentration of the
analyte in the sample. Specific gravity (refractometry
based) and clarity are measured in a flow cell, and color is
rated with a specific algorithm against the blank pad on
the test strip. Data are expressed in an ordinal scale (as
“normal”, “negative”, “positive”, or as nominal concen-
trations) on the reports, but (quantitative) reflectance data
can be downloaded to floppy disks.
biochemical investigations
Albumin in urine was measured immunonephelometri-
cally on 220 randomly selected samples with use of
commercially available Behring antibodies on a Behring
Nephelometer II analyzer (Dade Behring) standardized
against the widely accepted WHO/College of American
Pathologists Certified Reference Material 470. Glucose
was measured by a hexokinase method standardized
against Standard Reference Material 917a and Standard
Reference Material 965 (n  85), and total protein by a
pyrogallol red method (17 ) (n  129) with Standard
Reference Material 917a as a standard and commercially
available reagents for both measurement procedures
(Roche) on a Modular P system (Roche).
statistics
P values 0.05 were considered significant. Agreement
between automated flow cytometry and test strip data
was evaluated by Spearman rank analysis. Multiple re-
gression analysis was used to investigate a model relating
leukocyte esterase and hemoglobin field reflectance. The
lower limit of detection (18 ) was calculated as the mean
value 3 SD for a blank sample. Diagnostic accuracy was
assessed by ROC analysis using commercially available
statistical software (MedCalc®).
Results
dilution and pH
Alkalinization of urine gives rise to erroneous results in
particle counting. When monitoring our samples, we
found a median pH of 6.5 (95% interval, 5–8). Hence,
extremely alkaline urine samples were not present in the
samples we investigated. Dilution was also monitored
with a range of specific gravity of 1.005–1.033 and a
median result of 1.017.
reproducibility
The within- and between-run CVs for protein, leukocyte
esterase, hemoglobin, and glucose are summarized in
Table 1.
comparison of protein reflectance results,
albumin, and proteinuria
We found a close correlation between the log-transformed
albumin results (x) and the test strip reflectance results (y):
y (%)  68.2  9.26[logx (mg/L)]; Spearman r  0.825;
P 0.001; Fig. 1. Two discrepancies (0.9%) were found in
which the test strips on both automated strip readers
overestimated the urinary albumin concentration by 10-
fold.
Similarly, protein reflectance data and total protein
measurements correlated well (Spearman r  0.921; P
0.001), which is expected as long as the major protein is
albumin. The lower limit of detection was 25 mg/L (CV
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2.2%) (18 ). On the basis of ROC analysis, diagnostic
sensitivity was 86% (95% confidence interval, 78–92%)
and specificity was 84% (95% confidence interval, 76–
91%) for a reflectance value of 55.6% when the nephelo-
metric assay was used as the comparison method at a
cutoff of 30 mg/L (n  220; 113 positive and 107 negative
cases, respectively).
comparison of flow cytometric rbc and
hemoglobin reflectance results
Agreement was fair between the flow cytometric RBC
data (x) and the URISYS 2400 hemoglobin reflectance
measurements (y) for counts above the upper reference
limit (25  106 RBC/L on UF-100). The following regres-
sion equation was obtained: y (%)  78.2 19.4 logx (106
cells/L); Spearman r  0.680; P 0.001; Fig. 2. A lower
limit of detection of 8  106 cells/L (CV  1.2%) was
calculated.
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Fig. 1. Correlation between protein (albumin) results obtained by
quantitative test strip analysis (y) and albumin (x; Behring BN II
Nephelometer; n  220).
Protein field reflectance (y; %) 68.2 9.26 log(albumin; mg/L); Spearman r
0.825; P 0.001). The two outer solid lines represent the 95% prediction
interval around the regression line. The dashed lines represent the lower limit of
detection (  ) with the 2 SD limits (- - - -).
Fig. 2. Correlation between RBC counts (x; flow cytometry) and test
strip hemoglobin concentration (y) for RBC counts 25  106 cells/L
(n  96).
Hemoglobin reflectance (y; %)  78.2  19.4 log(RBC count; 106 cells/L);
(Spearman r  0.680; P 0.001. The two outer solid lines represent the 95%
prediction interval around the regression line. The dashed lines represent the
lower limit of detection (  ) with the 2 SD limits (- - - -).
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Because RBCs tend to lyse in urine, we investigated the
linearity of the hemoglobin test strip pad. The UF-100
flow cytometer automatically determines the conductiv-
ity, so we performed multiple regression analysis on the
study population, calculated in a regression model the
hemoglobin reflectance vs RBCs and conductivity, and
found that the t-value (as expected) for RBCs was 8.442
(P 0.0001). In contrast, conductivity showed a t-value of
only 1.477 (P  0.141). Additional dilution experiments
were carried out. The ratio of hemoglobin reflectance to
RBC count was constant when osmolality was 190
mosmol/L.
comparison of flow cytometric wbc and
leukocyte esterase reflectance results
The correlation between WBC data (x) and leukocyte
esterase measurements (y) is shown in Fig. 3. When
urinary WBC counts were higher than the upper reference
limit (25  106 cells/L), the following regression equation
was obtained: y (%)  83.7 15.4 logx (106 cells/L);
Spearman r  0.688; P 0.001. For WBCs, we found a
lower limit of detection of 19  106 cells/L (CV  1.2%).
Multiple regression analysis on the study population
showed no effect of conductivity on test strip leukocyte
esterase.
comparison of the glucose measurements
We also found good agreement between the hexokinase-
based glucose method (x) and glucose test strip reflec-
tance reading (y): y (%)  53.9  19.3 logx (mmol/L);
Spearman r  0.851; P 0.001. Fig. 4 depicts the
correlation between both measurement methods and the
lower limit of detection of 0.17 mmol/L (CV 1.3%) with
the 2 SD limits.
Discussion
The change from urine microscopy to urinary flow cytom-
etry has been accompanied by a significant decrease in
imprecision (15 ). Because urinalysis test strips are often
used for checking urinary flow cytometry data (11 ), there
is a need for a more quantitative evaluation of urinalysis
test strips. In this study, we compared the URISYS 2400
automated strip reader with the Sysmex UF-100 flow
cytometer to evaluate the possible value of quantitative
test strip data in a urinary expert system.
The turnaround time was short enough (2–4 h) not to
affect the readings: time intervals can influence results of
automated test strip analysis, especially leukocyte and
erythrocyte ratings (19 ).
The detection limit of the URISYS 2400 protein assay
was 25 mg/L if restricted to albumin alone and total
protein was not considered. Because microalbuminuria is
defined as excretion of 30–300 mg of albumin/24 h
(20–200 g/min, or 30–300 g/mg of creatinine) (20 ), the
protein field result allows identification of microalbumin-
uria cases in contrast to the classic reading and reporting
of the strips, which can detect only albumin concentra-
tions 150–200 mg/L or higher (21, 22). This implies that
the test has the potential to offer a screening for mi-
croalbuminuria without increased cost, hence coming
closer to the “urine test strip of the future” (23 ). This
could improve level 1 urinary screening (12 ): it offers an
improved, fast, reliable method that is easy to handle and
usable in primary-care laboratories. It could be of special
interest in patients with undiagnosed diabetes or hyper-
tension in whom microalbuminuria is regarded as an
excellent marker for assessing early renal damage (4–7),
particularly because many patients with non-insulin-de-
pendent diabetes mellitus are asymptomatic and their
diabetic state remains undiagnosed for years (24 ). It must
be noted, however, that the sensitivity (86%) may be
inadequate for patients with known diabetes in whom
physicians do not want to miss microalbuminuria in their
annual testing. Moreover, a 16% false-positive rate may be
unacceptable for screening.
Because microalbuminuria is characterized by large
intraindividual variability, an ordinal-scale answer might
Fig. 3. Regression equation for urinary WBC counts above the upper
reference limit (25  106 cells/L; n  132).
Leukocyte esterase reflectance (y; %)  83.7  15.4 log(WBC count; 106
cells/L); Spearman r  0.688; P 0.001. The two outer solid lines represent
the 95% prediction interval around the regression line. The dashed lines
represent the lower limit of detection (  ) with the 2 SD limits (- - - -).
Fig. 4. Correlation between glucose measurements (glucose concen-
tration different from 0) by the hexokinase-based method and glucose
test strip reading (n  85).
Glucose reflectance (y; %)  53.9  19.3 log(glucose; mmol/L); Spearman r 
0.851; P 0.001). The two outer solid lines represent the 95% prediction
interval around the regression line. The dashed lines represent the lower limit of
detection (  ) with the 2 SD limits (- - - -).
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be misleading. It therefore is advantageous to have a
better estimation of the true concentration.
As is the case for test strips in general, the method is
based on the so-called “indicator error” principle, in
which proton exchange between the indicator on the strip
and the proteins in the solution produces a color change
from yellow to green-blue. Of all the diagnostically rele-
vant urinary markers, only albumin and transferrin accept
protons well, so the potential error of missing Bence Jones
proteinuria remains when test strip screening strategies
are used in proteinuria (21 ), although many cases present-
ing with Bence Jones or tubular proteinuria show mi-
croalbuminuria (23 ).
In recent studies, the correlation (r) between UFC
WBCs and WBCs by counting chamber was 0.93–0.98,
and that of UFC RBCs and RBCs by counting chamber
was 0.83–0.89 (10, 25, 26). In our study correlating test
strip data with urinary flow results, r was 0.69 between
the flow cytometric WBC count and the leukocyte esterase
reaction, although the presence of esterase inhibitors in
urine and severe proteinuria might negatively affect test
results for leukocyte esterase (1, 27). No effect of conduc-
tivity on the leukocyte esterase field was noted. Test strip
measurements had reasonable lower limits of detection
for WBC (19  106/L).
In this study, the urinary hemoglobin concentration
did not agree well with the RBC count obtained by flow
cytometry. The hemoglobin measurement is based on the
peroxidase principle. It is known that reducing substances
(e.g., ascorbic acid) may lower the signal, whereas oxidiz-
ing substances may have a positive effect on measured
hemoglobin concentration. Various low- and high-molec-
ular mass inhibitors have been found in urine (28, 29).
The presence of haptoglobin in urine enhances the perox-
idase activity of hemoglobin (29, 30). Bacterial peroxi-
dases can also contribute to total peroxidase activity in
urine (23 ). On the other hand, the quantitative evaluation
of test strips may help to eliminate analytical errors in
RBC counting attributable to the presence of yeast cells or
large amounts of calcium carbonate crystals (11, 15). As
shown by our multiple regression model and dilution
experiments, the hemoglobin field reflectance test is not
influenced by dilution effects. As is the case for WBCs, the
lower limit of detection for RBCs is acceptable (8 
106/L).
The correlation coefficient for the glucose signal with
the routine hexokinase-based method was 0.851. The
presence of ascorbate oxidase on the glucose test field
prevents interference by ascorbic acid.
Because of the procedure for applying the urine to the
test strips on the URISYS 2400, improper dipping is no
longer a problem, nor is confusion about sample identifi-
cation or urine contamination caused by dipping the strip
in the tube, which potentially leads to interferences with
chromatographic methods (31 ).
In conclusion, quantitative urine test strip analysis pro-
vides reliable data on WBCs, RBCs, glucose, and albumin.
This offers several possibilities: (a) The sensitivity for
albumin may allow affordable screening for microalbu-
minuria, particularly in patients with undiagnosed renal
damage. To fully explore the possibilities of the albumin
test pad in first-line diagnosis, a formal study should be
performed. (b) In addition, hemoglobin and leukocyte
esterase reflectance data are useful for verifying flow
cytometric data on RBCs and WBCs. This leads to im-
proved elimination of occasional errors in the WBC and
RBC counting channels of the flow cytometer (11 ).
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Abstract
Background: Recently, automated urine test strip
readers became available that can report quantitative
data. We explored the possibility of measuring all
ketone bodies (acetone, acetoacetate, 3-hydroxy-
butyrate) in urine with these test strips. Monitoring
urinary ketone concentrations could offer the advan-
tages of measuring higher values (due to the low
renal thresholds) and being less sensitive to
fluctuations.
Methods: We evaluated URISYS 2400 (Roche) quan-
titative reflectance data for the ketone reflectance field
and compared it with biochemical data from urine
samples. Using an easy sample pre-treatment with
3-hydroxybutyrate dehydrogenase, we were able to
assay 3-hydroxybutyrate as well, which normally
does not react on urine test strips.
Results: Within- and between-run reproducibility of
the reflectance signal for high- and low-concentration
urine pools was 11.0–3.6% and 11.0–5.8% for aceto-
acetate, 8.2–9.2% and 10.4–16.1% for acetone, and
5.1–3.0% and 5.6–3.5% for 3-hydroxybutyrate, respec-
tively. The lower limit of detection for acetoacetate
was 0.13 mmol/L (CVs3.6%). Fair agreement was
obtained between test strip data for ketones and
colorimetrically determined acetoacetate values
(rs0.90).
Conclusions: In urine test strip analysis, quantita-
tive ketone reflectance data allow a simple and fast
analysis, offering affordable screening for the detec-
tion of ketone body production in diabetes, especially
in emergency settings.
Keywords: acetoacetate; diabetic ketosis; 3-hydroxy-
butyrate; reagent strip; urinalysis.
Introduction
In diabetes monitoring, there is growing interest in
monitoring the production of ketone bodies. In partic-
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Clinical Chemistry, University Hospital Ghent – 2P8,
De Pintelaan 185, 9000 Gent, Belgium
Phone: q32-9-2402956, Fax: q32-9-2404985,
E-mail: joris.delanghe@ugent.be
ular, for diabetics treated with an insulin infusion
pump, monitoring of acetoacetate (AcAc) and 3-
hydroxybutyrate (3HB) is of clinical importance (1–3).
As a primary source of energy for some organs and
a secondary or alternate source for others, low con-
centrations of ketone bodies are always found in the
blood and urine of a healthy reference population.
However, in response to certain stresses or in various
medical conditions, ketone body levels rise in both
blood and urine. The objective of routine ketone mon-
itoring, especially of 3HB and AcAc, is to detect and
thus prevent diabetic ketoacidosis (DKA). Acetone, the
third and least abundant ketone body, is responsible
for the characteristic ‘‘pear-drop’’ smell present in
DKA, but does not contribute to acidosis (4, 5).
Classically, the nitroprusside reaction (Ketostix,
Acetest) has been used to carry out semi-quantitative
assays of urinary ketones (6), mainly measuring AcAc.
The presence of ketone bodies in urine at concentra-
tions detectable by strips has long been recognized
as a symptom of DKA (6). However, since AcAc is
measured semi-quantitatively and the nitroprusside
reaction reacts weakly with acetone and does not reg-
ister the presence of 3HB, this technique has limited
value in judging DKA (2, 7). When 3HB is the only
ketone present, which can occur occasionally, the
color reaction underestimates the magnitude of
ketoacidosis (4, 5).
In DKA, the ratio of 3HB to AcAc increases from 1:1
to as much as 5:1. When acidosis resolves with treat-
ment, 3HB is oxidized to AcAc. Under these circum-
stances, urine tests may give the misleading
impression that ketosis is not improving (4). Nowa-
days, an expensive 3HB assay can be used on a hand-
held sensor (Optium meter; Medisense/Abbott,
Abingdon, UK) to measure this ketone body using
blood from a fingerprick test (8).
However, compared to the traditional nitroprusside
reaction on urine test strips, an accurate quantitative
assessment of all ketone bodies in urine could pro-
vide a much more valuable insight in determining cur-
rent metabolic status and treatment strategy. The
quantitative monitoring of ketone bodies could
improve evaluation of the therapeutic progress in
ketoacidosis in the clinical setting.
The value of test strip urinalysis has been thor-
oughly proven (9). The reproducibility of (semi-)auto-
mated reading is at least as good as visual reading
(10), but most authors find the analytical, clinical and
labor-cost saving advantages of (semi-)automated vs.
visual reading to be obvious (11). Some years ago,
the URISYS 2400 automated urine test strip analyzer
(Roche Diagnostics, Mannheim, Germany) was intro-
duced. This instrument offers the possibility to obtain
reflectance readings. Test results therefore no longer
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need to be expressed on an ordinal scale. Access to
the instrument’s raw data theoretically allows higher
analytical sensitivity (12).
In this study, we wanted to investigate the perform-
ance of quantitative measurements of urinary ketones
using reflectometry. Results were compared with
those of photometric methods for the determination
of AcAc and 3HB. Using a sample pretreatment with
3-hydroxybutyrate dehydrogenase (EC 1.1.1.30), the
possibility of analyzing urinary 3HB using quantitative
reflectometry was studied. Furthermore, we wanted
to explore the possibilities of quantitative ketone
measurements in a clinical setting.
Materials and methods
Test strip analysis
Test strip urinalysis was carried out using URISYS strips on
a URISYS 2400 analyzer (Roche Diagnostics) (12). The strips
include reagent pads for ordinal scale reporting of relative
density, pH, leukocyte esterase, nitrite, protein, glucose,
ketones, urobilinogen, bilirubin and hemoglobin/myoglobin.
The intensity of the reaction color of the test pad is detect-
ed by measuring the percentage of light reflected from the
surface to the test pad. A higher analyte concentration
results in greater color intensity, and thus in a lower reflec-
tance value. The reflectance value, expressed as a percent-
age within a range from 100% (white) to 0% (black), is
therefore inversely proportional to the concentration of the
analyte in the sample. Specific gravity (refractometry-based)
is measured in a flow cell and color is rated with a specific
algorithm against the blank pad on the test strip. Data are
expressed on an ordinal scale (as ‘‘normal’’, ‘‘negative’’,
‘‘positive’’ or as nominal concentrations) on the reports pro-
vided by the instrument, but (quantitative) reflectance data
can be exported to a laboratory information system or a net-
work environment.
Calibration of the flow cell and photometer was carried out
according to the manufacturer’s instructions. The reflecto-
metric assay was calibrated vs. aqueous lithium AcAc (Sig-
ma, St Louis, MO, USA) and acetone standards (Sigma).
These calibration curves were used to convert reflectance
values (% remission) into concentrations (mmol/L). Linearity
was tested in aqueous solutions over the range 0–14
mmol/L (acetone), and 0–20 mmol/L (acetoacetate). Repro-
ducibility was assessed using samples with low and high
analyte concentrations analyzed ten times in one run (within-
run CV) and on 10 consecutive days (between-run CV).
3-Hydroxybutyrate analysis
For the additional determination of 3HB, the sample was pre-
treated with 1230 U/L 3HB dehydrogenase (EC 1.1.1.30; Sig-
ma) and 4.64 mmol/L NADq (Sigma) in a glycine-NaOH
buffer solution (pH 9.0). 3-Hydroxybutyrate dehydrogenase
catalyzes the conversion of 3HB into AcAc, with concomitant
reduction of NADq to NADH. This buffer system is compat-
ible with the conditions required for the second reaction
step. After 20 min of pre-incubation, the sample is analyzed
quantitatively as AcAc on a urine test strip based on the
Legal reaction (sodium nitroprusside). The difference
between this final reading and the basic reading (without
pre-treatment step) is calculated and the result is compared
to a 3HB standard (Sigma). The linearity of the method was
tested in the same way as the quantitative test strip method
in the range 0–10 mmol/L.
Biochemical investigations
3HB in urine and serum was measured colorimetrically
according to Williamson (13) using commercial reagents
(Sigma) (ns9) on a Hitachi 911 analyzer (Hitachi, Tokyo,
Japan). Urinary AcAc was assayed according to Williamson
(13).
Interferences
Glucose was added in aqueous solution at concentrations
ranging from 0 to 110 mmol/L. 3HB was tested in the range
0–15 mmol/L. Electrical conductivity was varied by addition
of various NaCl solutions (final conductivity range from 5 to
30 mS/cm).
The effect of urinary pH on the test results was tested by
varying the pH of a urine sample containing 0–20 mmol/L
AcAc with sodium hydroxide (0.1 mol/L) from pH 5.0 to 9.0
in increments of 0.2 pH units.
Patients
The study protocol was approved by the Ethics Committee
of our hospital. A total of 18 diabetic patients (9 males, 9
females, 38"18 years) under insulin infusion pump treat-
ment were enrolled in the study. They were referred to the
endocrinology department because of diabetic ketoacidosis.
Urine and serum samples were collected for analysis. We
studied freshly collected urine samples submitted to our rou-
tine laboratory for diagnostic urinalysis. Samples were
stored at y208C upon arrival in the laboratory and analysis
was performed within 1 week.
Determinations of renal thresholds for 3HB and
AcAc
Renal thresholds for 3HB and AcAc were calculated by com-
paring serum and urinary AcAc measurements in three
female diabetes patients (age 16, 39, and 46 years). All
patients had a serum creatinine concentration within the
reference range and were under treatment with an insulin
infusion pump. The renal threshold was defined as the
extrapolated (linear regression) plasma concentration at
which the analyte first appeared in the urine.
Statistics
Values of p-0.05 were considered significant. The lower
limit of detection (14) was calculated as the mean val-
ue–3=SD for a blank sample.
Results
Reproducibility
Table 1 summarizes the within- and between-run CVs
for high and low concentrations of acetone (1.16 and
14 mmol/L), AcAc (1.3 and 15 mmol/L) and 3HB (1.3
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Table 1 Reproducibility of ketone measurements (ns10) on the URISYS 2400 analyzer on a urine pool spiked with aceto-
acetate, acetone and 3-hydroxybuyrate.
Acetoacetate 3-Hydroxybutyrate Acetone
CV, Mean CV, Mean CV, Mean
% concentration, % concentration, % concentration,
mmol/L mmol/L mmol/L
Within-run
High concentration 11.0 18.7 5.1 9.04 8.2 16.4
Low concentration 3.6 1.13 3.0 1.12 9.2 1.08
Between-run
High concentration 11.0 16.8 5.6 8.97 10.4 15
Low concentration 5.8 0.93 3.5 1.14 16.1 1.03
High concentration, 15 mmol/L for 3HB and AcAc, and 14 mmol/L for acetone. Low concentration, 1.3 mmol/L for 3HB and
AcAc, and 1.16 mmol/L for acetone.
Figure 1 Correlation between acetoacetate results obtained by quantitative test strip analysis and routine chemical deter-
mination (colorimetric method) (ns32): ketone field reflectance (mmol/L)s0.20q0.57 acetoacetate (mmol/L) (Spearman
rs0.90 and p-0.0001). The two outer lines represent the 95% prediction interval around the regression line.
and 15 mmol/L). Within- and between-run CVs for all
analytes were between 3% and 16%.
Calibration curves for acetone, AcAc and 3HB
For both acetone and AcAc, close correlation was
found between the reflectance readings and the ana-
lyte concentration in urine: y (1/ketone field reflec-
tance)s11.72 acetone (mmol/L)q5.23 (rs0.86); and y
(1/ketone field reflectance)s0.51 AcAc (mmol/L)q2.80
(rs0.98).
Over a broad concentration range (0–15 mmol/L),
3HB did not show any reaction with the test strips.
For 3HB in urine, the following correlation was
found after enzymatic pretreatment: y (1/ketone field
reflectance)s0.18 3HB (mmol/L)q1.92 (rs0.95).
Comparison between photometric and reflectance
ketone results
Fair agreement was found between the photometric
AcAc data and ketone measurements on the URISYS
2400. The following regression equation was
obtained: ketone field reflectance (mmol/L)s0.20
q0.57 AcAc (mmol/L) (Spearman rs0.90 and p-
0.0001; Figure 1). A lower limit of detection of 0.13
mmol/L (CVs3.6%) was calculated for AcAc.
Comparison of the 3HB measurements
Good agreement between the colorimetric 3HB con-
centration and test strip reading following 3HB dehy-
drogenase treatment was also observed: ketone field
reflectance (mmol/L)sy0.68q1.52 3HB (mmol/L)
(Spearman rs0.84 and p-0.01). Figure 2 depicts the
correlation between both measurement procedures.
Interferences in AcAc and 3HB measurement
For AcAc and 3HB determined by quantitative reflec-
tance reading, varying the urinary pH values over a
broad range (pH 5.0–9.0) did not result in a significant
change in reflectance reading. Glucose concentration
did not affect results in the range from 0 to 110
mmol/L. Changing urinary conductivity had no effect
on the test strip measurements.
In contrast to colorimetric assays, addition of 3HB
up to 15 mmol/L did not affect test results in the
reflectometric AcAc test.
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Figure 2 Correlation between 3-hydroxybutyrate results
obtained by quantitative test strip analysis and routine
chemical determination (colorimetric method) (ns19):
ketone field reflectance (mmol/L)sy0.68q1.52 3-hydroxy-
butyrate (mmol/L) (Spearman rs0.84 and p-0.01). The two
outer lines represent the 95% prediction interval around the
regression line.
Table 2 Acetoacetate and 3-hydroxybutyrate production in
diabetics under insulin pump treatment.
Age, years 38"18
Gender, males/females 6/6
Maximal serum AcAc, mmol/L 1.20
Maximal serum 3HB, mmol/L 8.37
Maximal urine AcAc, mmol/L 21.16
Maximal urine 3HB, mmol/L 37.70
Renal threshold for AcAc, mmol/L 38"7
Renal threshold for 3HB, mmol/L 180"70
Urinary creatinine, mmol/L 5.07"3.42
Figure 3 Typical evolution of serum and urinary AcAc and 3HB in a diabetic under insulin pump treatment: h urinary 3HB
(Hitachi); j urinary AcAc (Hitachi); s urinary AcAc (ketone field reflectance; URISYS 2400); m serum 3HB (Hitachi); * serum
AcAc (Hitachi).
Clinical data
In the diabetes patients, urinary ketone and 3HB
excretion was quantitatively monitored under insulin
pump treatment. Table 2 summarizes the major bio-
chemical data obtained under insulin pump treat-
ment. For 3HB and AcAc, renal threshold values were
180"70 and 38"7 mmol/L, respectively. Figure 3
depicts the typical evolution of AcAc and 3HB in
serum and urine during insulin pump treatment.
Discussion
In this study we demonstrated that the URISYS 2400
automated strip reader is able to provide quick and
accurate quantitative measurements of urinary
ketones. In the traditional urine test strip, color devel-
opment is much more intense for AcAc than for ace-
tone, and 3HB is not detected. Thus, in clinical
practice, the test path will almost exclusively detect
AcAc. However, it should be mentioned that in vivo
the highly volatile acetone is mainly eliminated by the
lungs (15). Only 1% of acetone is excreted via urine.
Moreover, since acetone is a volatile compound, the
pre-analytical requirements for obtaining accurate
determinations of urinary acetone are very difficult to
realize in a routine clinical setting. Isolated increases
in urinary acetone concentration have only occasion-
ally been observed following isopropanol intoxication
(16).
Additional quantitative determination of urinary
3HB was made possible using a simple pretreatment
step followed by reflectance measurement of the
ketone test path. Although not indispensable for clin-
ical practice, the latter measurement provides a more
complete picture of the patient’s metabolic state.
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When more accurate estimation of ketone produc-
tion is requested, a conventional ordinal-scaled result
might be misleading. Therefore, it is advantageous to
have a better estimation of the true concentration of
urinary ketones, including 3HB, by means of quanti-
tative reflectance readings. It offers an improved, fast
and reliable method that is easy to handle and usable
in primary care laboratories and could be of special
interest for insulin-dependent diabetes patients.
In the literature, false results have been reported for
qualitative ketone measurements using test strips.
False positive results are commonly reported when
the patient is taking sulfhydryl drugs (e.g., captopril,
N-acetylcysteine, mesna, dimercaprol and penicilla-
mine), while false negative results have been reported
in the presence of high concentrations of vitamin C.
In the case of diabetic ketoacidosis, test strip results
were not significantly affected by variations of urinary
pH. Furthermore, no significant effects of sample con-
ductivity and urinary glucose concentration on the
ketone test field were noted. In cases of extreme
dilute urine, correction of test results (e.g., according
to creatinine or conductivity) can be recommended.
In this study, the urinary ketone body concentration
agreed well with the colorimetric determination of
AcAc. The correlation coefficient for the reflectometric
ketone method compared to the routine enzymatic
method was 0.90. In contrast to the enzymatic AcAc
assay (in which 3HB significantly shifts the reaction
equilibrium towards AcAc), interference from 3HB on
the ketone test strip was negligible. The latter finding
is of importance, since in diabetic ketoacidosis, 3HB
is the major ketone body present.
Since urinary ketones represent a mean value of the
excretion rate, urine measurements are less sensitive
to biological variations than blood measurements.
Moreover, due to the very low renal threshold for
ketones, urinary ketone concentrations far exceed
those observed in blood, which is a major analytical
advantage. The stability of ketones in urine is excel-
lent (17).
The detection limit for the URISYS 2400 ketone
assay was 0.13 mmol/L (AcAc). The renal thresholds
observed for 3HB (180"70 mmol/L) and AcAc
(38"7 mmol/L) are well within the reference range of
these analytes in serum (30–650 mmol/L for 3HB and
15–220 mmol/L for AcAc) (18). The low renal threshold
for both AcAc and 3HB contributes to the good diag-
nostic sensitivity of their urinary determination.
The American Diabetes Association recommends
that anyone with diabetes perform urinary tests for
ketones during times of illness or stress, during preg-
nancy, when blood glucose levels of 17 mmol/L per-
sist, or whenever symptoms of ketoacidosis are
observed. The presence of precipitating factors that
contribute to the development of DKA would also
indicate that ketones should be monitored. While
diabetes type 1 patients are at particular risk, keto-
acidosis is increasingly recognized as a problem asso-
ciated with type 2 patients as well, especially those
who are insulin-dependent.
In diabetics treated with insulin pumps, checking
urine for ketones is important for reducing the mis-
diagnosis of DKA (e.g., due to undetected leakage of
the infusion system, infection, mismanagement of the
pump) (19, 20).
In conclusion, quantitative urine test strip analysis
provides reliable data on ketone body excretion. The
proposed method is simple and cheap, well suited for
the routine clinical laboratory and can be used in an
emergency setting. The high sensitivity for ketones
may allow screening for ketone production in diabe-
tes. In particular, the analysis allows monitoring of the
metabolic state of diabetics on insulin pump treat-
ment. Additional sample treatment with 3HB dehydro-
genase allows the analysis of 3HB, which yields a
more complete picture.
References
1. Guerci B, Benichou M, Floriot M, Bohme P, Fougnot S,
Franck P, et al. Accuracy of an electrochemical sensor
for measuring capillary blood ketones by fingerstick
samples during metabolic deterioration after continuous
subcutaneous insulin infusion interruption in type 1 dia-
betic patients. Diabetes Care 2003;26:1137–41.
2. Taboulet P, Haas L, Porcher R, Manamani J, Fontaine JP,
Feugeas JP, et al. Urinary acetoacetate or capillary
wbetax-hydroxybutyrate for the diagnosis of ketoacidosis
in the Emergency Department setting. Eur J Emerg Med
2004;11:251–8.
3. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R.
Insulin pump therapy: a meta-analysis. Diabetes Care
2003;26:1079–87.
4. Wallace TM, Matthews DR. Recent advances in the mon-
itoring and management of diabetic ketoacidosis. Q J
Med 2004;97:773–80.
5. Laffel L. Ketone bodies: a review of physiology, patho-
physiology and application of monitoring to diabetes.
Diabetes Metab Res Rev 1999;15:412–26.
6. Schwab TM, Hendey GW, Soliz TC. Screening for keto-
nemia in patients with diabetes. Ann Emerg Med 1999;
34:342–6.
7. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, Mc-
Donald JM, Parrott M. Guidelines and recommendations
for laboratory analysis in the diagnosis and manage-
ment of diabetes mellitus. Clin Chem 2002;48:436–72.
8. Byrne HA, Tieszen KL, Hollis S, Dornan TL, New JP. Eval-
uation of an electrochemical sensor for measuring blood
ketones. Diabetes Care 2000;23:500–3.
9. Bonnardeaux A, Somerville P, Kaye M. A study on the
reliability of dipstick urinalysis. Clin Nephrol 1994;41:
167–72.
10. Winkens RA, Leffers P, Degenaar CP, Houben AW. The
reproducibility of urinalysis using multiple reagent test
strips. Eur J Clin Chem Clin Biochem 1991;29:813–8.
11. Peele J, Gadsden R, Crews R. Semi-automated vs. visual
reading of urinalysis dipsticks. Clin Chem 1977;23:
2242–6.
12. Penders J, Fiers T, Delanghe JR. Quantitative evaluation
of urinalysis test strips. Clin Chem 2002;48:2236–41.
13. Williamson DH, Mellanby J, Krebs HA. Enzymatic deter-
mination of D-(–)-b-hydroxybutyric acid and acetoacetic
acid in blood. Biochem J 1962;82:90–6.
14. Westgard JO. Method validation – the detection limit
experiment. 2004 (http://www.westgard.com/lesson29.
htm).
15. Wigaeus E, Holm S, Astrand I. Exposure to acetone.
Uptake and elimination in man. Scand J Work Environ
Health 1981;7:84–94.
Penders et al.: Quantitative test strip data in monitoring ketone bodies 729
Article in press - uncorrected proof
16. Pappas AA, Ackerman BH, Olsen KM, Taylor EH. Isopro-
panol ingestion: a report of six episodes with isopropa-
nol and acetone serum concentration time data. J
Toxicol Clin Toxicol 1991;29:11–21.
17. Froom P, Bieganiec B, Ehrenrich Z, Barak M. Stability of
common analytes in urine refrigerated for 24 h before
automated analysis by test strips. Clin Chem 2000;
46:1384–6.
18. Kientsch-Engel RI, Siess EA. D-(–)-3-Hydroxybutyrate
and acetoacetate. In: Bergmayer HU, editor. Methods of
enzymatic analysis. Metabolites 3: lipids, amino acids
and related compounds. Weinheim: VCH Publishers,
1985:60–9.
19. Walter H, Gunther A, Timmler R, Mehnert H. Ketoaci-
dosis in long-term therapy with insulin pumps. Inci-
dence, causes, circumstances. Med Klin (Munich) 1989;
84:565–8.
20. Walter H, Gunther A, Timmler R, Mehnert H. Diabetic
ketoacidosis during insulin pump therapy. Dtsch Med
Wochenschr 1989;114:706–8.
Received February 16, 2005, accepted May 16, 2005
  
 
 
 
 
 
 
Chapter 3 C 
 
Alpha 1-microglobulin: 
clinical laboratory aspects 
and applications 
 
 
 
Joris Penders and Joris R. Delanghe 
Clinica Chimica Acta 2004; 346: 107– 118 
 
 
  
www.elsevier.com/locate/clinchim
Clinica Chimica Acta 346 (2004) 107–118Review
Alpha 1-microglobulin: clinical laboratory aspects and applications
Joris Penders, Joris R. Delanghe*
Department of Clinical Chemistry, University Hospital Ghent-2P8, De Pintelaan 185, B-9000 Ghent, BelgiumReceived 4 December 2003; received in revised form 22 March 2004; accepted 24 March 2004Abstract
Background: Urinary microproteins are becoming increasingly important in clinical diagnostics. They can contribute in the
non-invasive early detection of renal abnormalities and the differentiation of various nephrological and urological pathologies.
Alpha 1-microglobulin (A1M) is an immunomodulatory protein with a broad spectrum of possible clinical applications and
seems a promising marker for evaluation of tubular function. Method: We performed a systematic review of the peer-reviewed
literature (until end of November 2003) on A1M with emphasis on clinical diagnostic utility and laboratory aspects.
Conclusions: A1M is a 27-kDa glycoprotein, present in various body fluids, with unknown exact biological function. The
protein acts as a mediator of bacterial adhesion to polymer surfaces and is involved in inhibiting renal lithogenesis. Because
A1M is not an acute phase protein, is stable in a broad range of physiological conditions and sensitive immunoassays have been
developed, its measurement can be used for clinical purposes. Unfortunately, international standardisation is still lacking.
Altered plasma/serum levels are usually due to impaired liver or kidney functions but are also observed in clinical conditions
such as HIV and mood disorders. Urinary A1M provides a non-invasive, inexpensive diagnostic alternative for the diagnosis
and monitoring of urinary tract disorders (early detection of tubular disorders such as heavy metal intoxications, diabetic
nephropathy, urinary outflow disorders and pyelonephritis).D 2004 Elsevier B.V. All rights reserved.Keywords: Proteinuria; Heavy metal intoxication; Renal disease; Urinary tract infection; Tubular function
1. Introduction less invasive techniques. For many years, beta 2-The evaluation of renal tubular function is an
important issue in clinical laboratory medicine. De-
tection of urinary microproteins can help to detect
renal abnormalities at an early stage and differentiate
the various forms of renal and urological pathology by0009-8981/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.cccn.2004.03.037
Abbreviations: A1M, alpha 1-microglobulin; IgA, immunoglo-
bulin A; IL, interleukin; UT, ulinastatin.
* Corresponding author. Tel.: +32-9-240-2956; fax: +32-9-240-
4985.
E-mail address: joris.delanghe@ugent.be (J.R. Delanghe).microglobulin has been a golden standard urinary
marker protein. However, the diagnostic utility of this
protein is hampered by its poor stability at acid pH.
The stable microprotein alpha 1-microglobulin (A1M)
offers an interesting alternative for evaluating tubular
function.
Furthermore, A1M is an intriguing multifunctional
immunomodulatory protein. Numerous studies have
revealed a broad spectrum of clinical applications.
This review aims at giving an overview of recent
developments in the basic knowledge, analysis and
clinical use of A1M. To accomplish this, we have
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reviewed literature until November 15, 2003.2. Structure and function of A1M
2.1. Synthesis and genetics
A1M is encoded by a unique gene encoding both
A1M and another protein, bikunin, which has no other
known relation to A1M than the co-synthesis [1]. The
gene is translated into the A1M-bikunin precursor,
which is subsequently cleaved. Bikunin is the small,
active subunit of protein/carbohydrate complexes that
constitute the inter-alpha-inhibitor family [2].
The human AMBP gene has been cloned [3] and
has been mapped to the 9q32–33 region [4]. The
AMBP gene has a weak minimal promoter [5]. A
specific enhancer accounts for the pronounced expres-
sion of A1M in the liver. In spite of the stable A1M
plasma concentration, the expression of its gene is up-
or downregulated during inflammation [6,7]. This is
in agreement with the presence of cis-acting elements
upstream of the gene with potential interleukin (IL)-6-,
interferon- and tumor necrosis factor-responsive
sequences [5]. The data show a discrepancy between
the up- and downregulated AMBP gene and the stable
A1M concentrations.
2.2. Structure
A1M is a 27-kDa glycoprotein produced by the
liver [8]. It was isolated in 1975 [9–11] and has been
designated other names, e.g. protein HC [12] and
alpha 1-microglycoprotein [13]. It belongs to the
lipocalin superfamily of hydrophobic ligand-binding
proteins forming an internal ligand-binding pocket
[2,14]. A1M is well conserved in evolution and has
been found in mammals [1], birds [15], amphibians
[16], and fish [17], but not (yet?) in reptiles. Among
the lipocalins, complement factor C8-gamma and
A1M have the closest relationship [18]. A relationship
between epididymal retinoic acid-binding protein and
A1M was demonstrated [19].
The protein consists of 183 amino acid residues
[1]. A free reactive cysteine side chain at position
Cys34 is engaged in complex formation with plasma
proteins and in binding to a yellow-brown chromo-phore. The color is caused by chromophore prosthetic
groups, covalently bound to amino acid residues at the
entrance of the lipocalin pocket [20]. Different chro-
mophores explain the charge and size heterogeneity of
A1M [21]. A 282-Da lipophilic substance (a candidate
ligand) was co-purified [20]. Several hydrophobic
substances, e.g. retinol, were extracted from the pro-
tein [22]. A1M is substituted with oligosaccharides in
three positions, two sialylated complex type, linked to
Asn17 and Asn96, and one oligosaccharide linked to
Thr5 [23]. Asn96 has both diantennary and trianten-
nary structures attached in the case of urinary A1M
[24].
2.3. The plasma complexes
In human plasma, approximately 50% of A1M
forms a 1:1 complex with monomeric immunoglobu-
lin A (IgA) by a reduction-resistant bond between the
penultimate cysteine in the alpha-chain and Cys34 of
A1M [25,26]. Approximately 7% is linked to albumin
[12,27] and 1% by a disulfide bond to prothrombin
[27]. In rat serum, A1M was found covalently linked
to fibronectin [28] and to alpha 1-inhibitor-3, a
homologue of human alpha 2-macroglobulin [29]. It
is not known where any of the A1M complexes are
formed.
Characteristic forms of high-molecular weight
A1M are present in pathological plasma: A1M has a
tendency to bind to mutated forms of coagulation
factors where a free Cys residue has been introduced.
Circulating complexes between A1M and factor IX
Zutphen [30], factor XII Tenri [31], and protein C
mutants [32] have been identified.
2.4. Physiology
After secretion to blood, A1M exists in free form
as well as in a variety of high molecular mass
complexes. Free, monomeric A1M passes through
the glomerulus out into the primary urine, from which
it is reabsorbed by the proximal tubules where catab-
olization occurs [2,33,34]. The endocytic receptor
megalin mediates the reabsorption of A1M [34].
Normal urine contains very small amounts of
A1M. In conditions with disturbed tubular function,
reabsorption of A1M is reduced and increased
amounts are found in urine. The plasma concentration
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mainly determined by the glomerular filtration rate
(GFR).
With the exception of the central nervous system,
the protein is found in most, if not all tissues: liver,
plasma, and kidney are major sites of A1M localiza-
tion [35]. This reflects the major phases of the
metabolism of A1M [8]. The protein is present in
the perivascular connective tissue of most organs
[36,37]. This matrix-A1M is distributed at interfaces
between cells and the external environment (blood/
tissue, air/tissue, intestinal lumen/villi) as well as at
the interface between maternal blood and fetal tissues
in placenta. Also in fetuses, a dominant role of liver
and kidney in A1M metabolism was found [36].
2.5. Function of A1M
A1M deficiency has not been reported in any
species, suggesting that its absence is lethal and
indicating its important physiological role [36].
The plasma concentration is markedly constant
during inflammation. One possibility is that A1M
exerts a constant immunosuppression, protecting rest-
ing tissues, but a local immune response may override
the suppression of A1M by a cytokine release. An-
other possibility is that A1M has an increased immu-
nosuppressive role at biological interfaces where it is
present at high concentrations. An example of this is
the placenta, where A1M (in free form as well as in
complexes not found in blood) protects the fetus from
attack by the maternal immune system [37]. t-A1M
(t = truncated), an A1M species with a free Cys34 thiol
group, is released from IgA-A1M as well as from free
A1M when exposed to the cytosolic side of erythro-
cyte membranes or to oxyhemoglobin. The processed
t-A1M (present in urine) binds heme [38] and partic-
ipates in heme degradation. A protective role of A1M
against the exposed heme on erythrocyte membranes
is suggested. A1M is found extracellularly [39,40] and
executes its heme-degradation functions outside the
cells [38,41]. IgA-A1M serves as a depot of A1M
from which A1M is released and processed locally as
soon as the erythrocyte ruptures. The size of IgA-
A1M prevents the molecule from glomerular filtration
and loss from the circulation.
Both free monomeric A1M and high-molecular
weight A1M are widely distributed in extravascularcompartments [39,40]. A truncated form of A1M
which might be identical to t-A1M is associated with
the placenta membrane. During inflammation and
necrosis, an activation of free A1M and IgA-A1M
occurs in ruptured cells. A1M interacts with heme-
binding proteins such as cytochrome c. The urinary t-
A1M may originate from extravascular tissue [42].
A1M plays an immunoprotective/anti-inflammato-
ry role. An inhibitory effect of A1M–collagen com-
plexes on monocyte free radical and IL-1-beta
production was described [43], as well as an inhibition
of the antigen-induced cell division of peripheral
blood lymphocytes [44,45]. Antigen-induced IL-2
production by T helper cell hybridomas [46], leuko-
cyte migration [44], and chemotaxis [47] are inhibited
by A1M. A mitogenic effect on resting lymphocytes
was observed [45,48,49], which was suppressed by
serum [49]. The N-linked oligosaccharides of A1M
inhibit antigen-induced lymphocyte proliferation sim-
ilar to that of intact A1M [50]. A1M binds to the
surface of B and T lymphocytes [51], NK cells [51],
the histiocytic cell line U937 [52]. The affinity of
A1M for its receptor on T cell hybridomas and
lymphocytes was low, 104–105 [48], and 107 on the
U937 cell line [52].
2.6. Adsorption–adhesion properties
The adsorption of the protein from serum, cerebro-
spinal fluid, urine and peritoneal dialysis fluid onto
polystyrene surfaces was suggested. In urine, the
analysis was extended to polyurethane and silicone
stents. The ease of desorption of A1M correlated with
surface hydrophobicity of the stent biomaterial. A1M
was removed from glass by water washing but re-
quired a 30% isopropanol wash to desorb from
polystyrene, implying attachment via hydrophobic
bonding. The adhesion to polystyrene surfaces by
Pseudomonas aeruginosa B4, an isolate from a uri-
nary tract infection, was strongly associated with the
presence of A1M, which may act as a mediator of
bacterial adhesion [53,54]. However promising these
results, further clinical evidence regarding the role of
A1M in foreign body infections, is still lacking.
Similar to the case for bikunin, A1M is a potent
inhibitor of calcium oxalate crystallization in a dose-
dependent manner. Urinary A1M concentration was
significantly lower in calcium oxalate stone formers
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of A1M in calcium oxalate stone formers could be
responsible in these patients for an increased risk of
crystalluria [55].3. Clinical laboratory aspects
3.1. Methods
Various immunoassays for the measurement of
A1M have been introduced. Early assays for A1M
involved electroimmunoassay and single radial im-
munodiffusion [9,14,56,57]. Later on, solid phase
radioimmunoassay followed [58]. Automated immu-
noassays using polystyrene particles coated with
antibodies (allowing ‘‘kinetic’’ assays) as well as
enzyme immunoassays have been developed [59].
Analytical sensitivities as low as 0.8 mg/l were
reported with a between-run imprecision (CV) of
11–16% [59].
IgA-bound and free forms were assayed using two
separate electroimmunoassays [14]. Fernandez-Luna
et al. [60] reported a two-step ELISA, whereas Vin-
cent and Revillard [61] used two separate ELISA
assays. De Mars et al. [62] developed a simultaneous
enzyme-linked immunoenzyme/immunoradiometric
assay that involved three different monoclonal anti-
bodies. A competitive ELISA was described for a
renal profile involving A1M [63].
Commercially available reagent strips are prepared
either with the goal of detecting albumin. Typically,
these dipsticks will change color if the protein in urine
is at least 400–600 mg/l for microproteins like A1M.
Pugia et al. [64] reported on a new total protein
dipstick that showed better chemical sensitivity and
agreement, especially for low-molecular weight pro-
teins, with a quantitative procedure as compared to
other dipsticks.
Jung et al. [65] described an immunochemical test
strip for the determination of A1M in urine that could
be suitable for screening purposes if methodical
improvements were made.
For nephelometric methods, a lowered precision
was only described for high urine calcium concen-
trations (>7.5 mmol/l), probably due to protein
denaturation by calcium hydroxide in alkaline urine
[60].Correlation between values obtained with various
standards was good. Between-method comparison
revealed marked differences possibly because the
standards used were of different origins, indicating
the necessity of standardisation of the determination
of A1M [59] as the case for beta 2-microglobulin.
3.2. Sample stability
In most reports, unlike beta 2-microglobin, A1M
was found to be stable in human urine ex vivo at
different pHs and therefore suitable as a marker of
tubular injury [62,67]. Donaldson et al. [68] found
that the stability of A1M, beta 2-microglobulin and
retinol binding protein was affected by urinary pH and
recommended alkalinisation performed at the time of
voiding. This apparent contradiction might be
explained by the fact that samples were at room
temperature for varying periods in the latter study.
A1M is stable in urine stored with or without
preservative at room temperature for 7 days and up
to 21 days at 4,  20 and  70 jC [66,69,70].
Stability studies of A1M in native urine stored at
 20 jC demonstrated significant decreases of the
concentration after 12 months. Addition to urine of a
preservative solution containing benzamidium chlo-
ride, ethylene-diamene-tetraacetate, tris(hydroxy-
methyl)-aminomethane and azide preserved A1M
[71].4. Clinical aspects
Table 1 summarizes the most important conditions
related to A1M and its concentration. The major
clinical application remains the use of urinary A1M
as a marker for proximal tubular damage. The other
potential applications are less documented.
A1M levels are very stable in several pathological
conditions: no significant changes were seen in serum
of patients with neoplastic diseases, central nervous
system disorders, infections, rheumatoid arthritis and
other disorders [56,58,72]. With a few exceptions,
altered total A1M concentrations in plasma or serum
are always related to impaired liver or kidney func-
tions. A striking exception is the decreased A1M
value in an early, non-symptomatic stage of HIV
infection [73]. Since the protein is synthesized in the
Table 1
Clinical pathology and A1M
Biological
fluid/tissue
Concentration Condition
Plasma/
serum
Increased Decreased glomerular filtration rates
[75]. In non-IgA myeloma-related
renal disease, total and free A1M
values for serum correlated well
with values for creatinine and beta
2-microglobulin in serum [62]. It
can be used for monitoring renal
function [77]. In malignant
melanoma, the value of the free and
IgA-complexed forms correlated
with the clinical stage [82].
Unchanged Acute phase reactions, neoplastic
diseases, central nervous system
disorders, infections, rheumatoid
arthritis and hepatitis [58,72,119].
Decreased Early, non-symptotic HIV infection
[73], severe liver insufficiencies
[72,74,119], compensated and
decompensated liver cirrhosis [58].
Urine Increased Impaired tubular function [56,76,
79–81]: heavy metal intoxication.
Balkan nephropathy [90]. Following
renal colic and chronic ureteral
obstruction. Grade of vesicoureteral
reflux, detrusor pressure and
compliance [99]. Nephropathy in
diabetics [92]. Decreased glomerular
filtration rates [75].
Mood
disorders
A1M and ulinastatin afford a useful
objective index when monitoring
patients with disorders [105–107].
Liver Distinction between primary
(hepatocellular carcinoma) and
secondary liver neoplasms [74].
Table 2
Review of commonly used tubular marker proteins
Marker Molecular
mass
(kDa)
Endocytic
tubular
receptor [34]
Remarks
Alpha 1-
microglobulin
27 Megalin Marked stability
over a wide
pH range
no standardisation
Beta 2-
microglobulin
11.8 Megalin Not stable at
acid pH
no standardisation
Retinol binding
protein
21 Megalin No sensitive assays
available (yet)
Clara cell protein 16 Cubilin and
megalin
Rarely used
N-acetyl-beta-D-
glucosaminidase
>130 ? Lysosomal
storage, activity
measurement
(potential
interference)
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serum level [58,72,74]. The plasma concentration of
free A1M is, in contrast to that of A1M-IgA, mainly
determined by the GFR [75]. Like other microproteins
in serum (i.e. cystatin C, beta 2-microglobulin) the
plasma concentration of A1M can be used for deter-
mination of the GFR even in the creatinine-blind
range, due to higher diagnostic sensitivity: a signifi-
cant positive correlation between serum A1M and
creatinine levels was found (r = 0.75, p < 0.001). Frac-
tional clearance of A1M increases proportionally to
the decrease of creatinine clearance [76]. In patients
with non-IgA myeloma-related renal disease, total and
free A1M values for serum correlated well with serumvalues for creatinine (r= 0.816 and 0.732 for total and
free A1M, respectively) and beta 2-microglobulin
(r = 0.791 and 0.696, respectively) [62] and is one of
the parameters that are very useful in monitoring renal
function in multiple myeloma patients [77].
4.1. Nephrological disorders
Tubular proteinuria results when glomerular func-
tion is normal, but the proximal tubules have dimin-
ished capacity to reabsorb and catabolize proteins,
causing an increased urinary excretion of the low-
molecular mass proteins that normally pass through
the glomerulus, such as retinol-binding protein,
A1M, beta 2-macroglobulin and Clara cell protein.
Since these products are present in the plasma in low
concentrations, urine protein excretion in tubular
proteinuria is usually < 1.5 g/day. Table 2 summa-
rizes the physical and physiological properties of
some proteins commonly used for assessing tubular
function.
Free A1M is found in normal urine, whereas none
of the complexes can be detected [10,12,78]. The
urinary concentration of free A1M is a sensitive
indicator of impaired tubular function [76,79–83].
There are many causes of tubular proteinuria.
Nephrotoxic substances that damage the tubule in-
clude heavy metals (e.g. cadmium and lead) and some
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and IgA-A1M separately in normal serum or plasma
[60–62,71,109].
Reference intervals for A1M are gender-dependent.
Moreover, a marked difference was noted in A1M
excretion rate during the day. Expressing A1M excre-
tion rate as protein/creatinine is an improved practical
estimate of the excretion rates [110,111]. The geomet-
ric means (and SD) of protein excretion rates in
normal subjects were as follows: 1.11 Ag/min (2.22);
and A1M, 0.98 Ag/min (2.36) [63].
A1M-IgA complex has great range, from undetect-
able concentrations (urine, colostrum and cervical
mucus) up to 59.2 mg/l in blood plasma. Undetectable
concentrations of A1M-IgA complex were also shown
in serum from patients with IgA immune deficiency
and in cerebrospinal fluid from patients with multiple
sclerosis. Increased concentration of A1M were noted
in bronchoalveolar fluid from a patient with pulmo-
nary alveolar proteinosis, serum from patients with
Behcet syndrome and in synovial fluid from patients
with gout, chondrocalcinosis and rheumatoid arthritis.
On the other hand, the concentrations of A1M-IgA
complex were raised only in those patients with
pulmonary alveolar proteinosis or rheumatoid arthritis
[109]. Takagi et al. [57] found mean A1M concen-
trations of 20.8 mg/l in synovial fluid, 28.7 mg/l in
ascites, 21.5 mg/l in pleural effusion, 2.7 mg/l in
amniotic fluid, 8.2 mg/l in cyst fluid and 42.3 ng/ml
in cerebrospinal fluid.6. Post-analytical aspects
Results of measuring urinary marker proteins are
still difficult to interpret. Using a parameter set in-
cluding A1M, it was possible to separate various renal
diseases by analysis of second morning urine. In order
to compensate for variation due to urinary dilution,
usually creatinine excretion is used [62,110,112,113].
A1M was useful to separate primary glomerulopathies
from tubulo-interstitial diseases. Application of these
techniques can help to detect renal abnormalities at an
earlier stage and differentiate the various forms by less
invasive techniques [112,113]. A clear separation of
primary glomerulopathies from tubulo-interstitial ne-
phropathies was possible at albumin excretion rates
between 4 and 1000 mg/g creatinine. All 42 patientswith interstitial nephropathy exhibited elevated A1M
above 14 mg/g creatinine, whereas 42 out of 45
patients with a primary glomerulopathy and an albu-
min excretion below 1000 mg/g creatinine showed
normal A1M excretion rates. Only at higher albumin
excretion (>1000 mg/g creatinine) the A1M concen-
tration tended to be elevated with increasing albumin-
uria [113].
Various computer-based expert systems for urine
protein differentiation have been developed in which
A1M data are used for the evaluation of renal tubular
function. Based on a data set including A1M, in
combination with a test strip screening, the findings
of hematuria, leukocyturia and proteinuria can be
assigned to prerenal, renal or postrenal causes, using
a computer-based expert system for urine protein
differentiation (‘‘UPES’’) as a decision-supporting
tool. In several clinical studies, this reached 98%
concordance with clinical diagnoses and was superior
to the diagnostic interpretations of experts. UPES has
been successfully integrated into the laboratory rou-
tine process [114–117]. Similarly, software was de-
veloped for classifying patterns of specific urinary
proteins. Measurement of urinary albumin and A1M
is mandatory where kidney disease is suspected, has
to be ruled out, or requires monitoring, even when the
total protein concentration is normal [118].7. Conclusion
A1M is an immunosuppressive protein with an
unknown exact biological function. Many unusual
and intriguing properties of the protein have been
revealed. The protein acts as a mediator of bacterial
adhesion to polymer surfaces and might play a role in
renal lithogenesis. In the clinical laboratory, sensitive
immunoassays allow us to use A1M determination for
clinical purposes. Although A1M is not an acute
phase protein, changes in the plasma/serum concen-
trations have been observed in several clinical con-
ditions such as HIV and mood disorders. Assaying
urinary A1M provides a non-invasive inexpensive
diagnostic alternative for the diagnosis and monitor-
ing of urinary tract disorders (early detection of
tubular disorders such as heavy metal intoxications,
diabetic nephropathy, urinary outflow disorders, and
pyelonephritis). Computer-aided interpretation of pa-
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agents and analgesics). Tubular proteinuria is also
associated with acute and chronic pyelonephritis,
renal vascular diseases, kidney transplant rejection,
Fanconi syndrome, and Balkan nephropathy.
Determination of urinary A1M has been used in
intoxications with heavy metals: a diagnostic ap-
proach to screen for nephrotoxity due to environ-
mental hazards like cadmium should include A1M.
Fels et al. [84] demonstrated that a model combining
urinary A1M with other glomerular and tubular
analytes, correctly classified 71% of workers with
a body burden of 15 Ag cadmium/g creatinine or
more. Additionally, Jung et al. [85] found that in
groups exposed to cadmium, either environmentally
or occupationally, 22% and 32%, respectively, had
urinary A1M values significantly exceeding these
from the control group ( p< 0.05), which was better
than all other urinary proteins investigated. A1M
was increased in the exposed persons whose cadmi-
um excretion was < 5 Amol/mol creatinine [65].
Combined determination of uncorrected urinary
A1M and N-acetyl-beta-D-glucosaminidase was rec-
ommended for screening to detect cadmium-induced
renal dysfunction at an early stage. Certainly in mass
screening, this combination performs better than beta
2-microglobulin or retinol binding protein as dem-
onstrated by comparing the correlation coefficients: r
values for A1M and N-acetyl-beta-D-glucosamini-
dase were significantly greater (p < 0.01) than these
for the other two proteins (r = 0.493 and 0.348,
0.275, respectively) [86].
Also in the case of occupational lead and mercury
exposure, urinary A1M was used as an early marker
of nephropathy [87,88].
A1M was used as a biomarker for demonstrating
damage caused by carcinogens like dinitrotoluene
directed towards the renal tubular system. A dose-
dependence of the excretion of urinary biomarker
proteins with the ranking of exposure was seen [89].
Urinary A1M as a tubular marker and albumin as a
glomerular were successfully used as an early marker
in the endemic regions of Croatia (Balkan nephropa-
thy) [90]: 90% of diseased subjects had an A1M level
of more than 15 mg/g creatinine. This can allow an
early diagnosis of tubular proteinuria but extensive
clinical and laboratory examinations must be per-
formed for a definite clinical diagnosis.In idiopathic membranous nephropathy, excretion
of IgG and A1M was associated with the extent of
tubulointerstitial damage (p = 0.0087 and 0.0024, re-
spectively, for score 0 to 1 versus greater than 2). Only
A1M excretion was associated with global glomerular
sclerosis and arteriolar hyalinosis ( p = 0.0032 and
0.0004, respectively). Excretion of IgG and A1M
has a predictive value for both remission and progres-
sion and is useful to identify patients at risk for
progression and for whom immunosuppressive thera-
py is indicated [91].
In addition to albuminuria (which measures glo-
merular dysfunction), urinary A1M is useful for the
early detection of nephropathy in diabetic subjects
[92,93]. A1M was used as a marker for the early
stages of diabetic nephropathy in NIDDM. The prox-
imal tubules are damaged as early as during the period
of subclinical diabetic nephropathy [93].
Increased urinary excretion of A1M may also
occur in other diseases without any apparent tubular
defect. Among these conditions are severe reductions
in the glomerular filtration with accumulation of A1M
in blood and a consequent overload of the few
remaining nephrons in their capacity to reabsorb
proteins.
In renal and bone marrow transplant recipients,
serum A1M is a complement to serum creatinine
levels in the evaluation of renal function: positive
linear correlations were found in both situations
(r = 0.7–0.8; p < 0.001) [94,95]. Urinary and serum
A1M are significantly higher in cyclosporine than in
azathioprine treatment and can therefore be an early
indicator in the choice of the immunosuppression
[94,96].
4.2. Urological disorders
Urinary A1M excretion was successfully used in
the diagnosis of various urological conditions involv-
ing kidney damage. Urinary A1M excretion is diag-
nostically useful in vesicoureteral reflux patients,
increases with higher intravesical–intrapylic pres-
sure, correlates with the decrease in absolute DMSA
uptake or with urinary epidermal growth factor
excretion and predicts the outcome after the treat-
ment. A1M is also useful in detecting renal tubular
damage in patients with outflow disease of the upper
tract [97]. In partial ureteral obstruction, urinary
Table 3
Reference values for total A1M and IgA-A1M in some biological
fluids
Biological
fluid
Form of
A1M
Reference/cut-off value Reference
Serum free A1M 3.5 Amol/la [62]
IgA-A1M 2.6 Amol/la [62]
total A1M 4.6 Amol/la [62]
Plasma free A1M 11.7 mg/l [109]
IgA-A1M 59.2 mg/l [109]
Urine A1M 0.31 Amol/la [62]
A1M upper 95 reference limit:
1.27 g/mol creatinine
(age 18–40) and 2.20 g/mol
creatinine (age >40)
[111]
IgA-A1M not detectable [62,109]
a Upper limit of observed range.
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age, but not for the condition as such [97,98].
Following renal colic and chronic ureteral obstruc-
tion, an increase in urinary A1M excretion was
observed while creatinine clearance or age had little
and gender had no influence on the urinary A1M
excretion. A1M excretion was related to the grade of
vesicoureteral reflux with a sensitivity of 90%, a
specificity of 70% and a predictive value of 97%
[99,100].
In the absence of specific symptomatology in
children and neurogenic bladder disease patients,
early diagnosis of acute pyelonephritis is a challenge.
The urinary A1M/creatinine ratio was highly sensitive
and specific (98–100% and 100–87% for Ref. [101]
and Ref. [102], respectively) and correlated with
DMSA scintigraphy. The drop in DMSA uptake
correlated (r = 0.758, p < 0.001) with the urinary
A1M excretion and the excretion was significantly
higher in bilateral than in unilateral pyelonephritis
(p < 0.02). The area under the curve of the ROC-curve
was significantly higher for A1M than for albumin or
gamma-glutamyltransferase (0.895, 0.654 and 0.512,
respectively, p < 0.001). In contrast to cystitis, elevat-
ed urinary A1M excretion is seen in acute pyloneph-
ritis [100–102].
Mantur et al. [103] demonstrated the usefulness of
the urinary A1M/creatinine ratio as a marker of
proximal kidney tubule damage in children with E.
coli and Proteus sp. infections.
Unexpected positive results were found in acute
prostatitis. Urinary A1M, alpha 2-macroglobulin and
albumin provide optimal differentiation between acute
pyelonephritis and acute prostatitis (pseudo R2 = 0.83;
log likelihood  30.55, p < 0.000001) [104].
4.3. Other disorders
The relationship between the urinary contents of
A1M and ulinastatin (UT) and the relation between
the serum contents of the free forms of A1M and UT
in patients with mood disorders is different from that
of healthy subjects. The regression plot between
scores of the Hamilton Scale for Depression and ratios
of the free form content to total content of UT is more
informative on the depressive state than that of A1M.
Changes in the slope of the regression plot correlating
between urinary contents of A1M and UT may afforda useful objective index when monitoring patients
with mood disorders [105–107].
Urinary levels of A1M and of UT and the A1M/UT
ratio did not differ between controls and patients with
Parkinson’s disease. The non-existence of a correla-
tion between A1M and UT levels distinguishes Par-
kinson’s disease from other neuropsychiatric diseases
such as dementia (Alzheimer-type and vascular de-
mentia), schizophrenia and mood disorder [108].
A1M is a marker for the hepatocytic lineage and
therefore could be useful for the distinction between
primary (hepatocellular carcinoma) and secondary
liver neoplasms [74].
The measurement of A1M and complexes with IgA
in plasma has, with few exceptions, not shown any
clinically interesting findings. However, in malignant
melanoma, the values of the free and IgA-complexed
forms correlated with the clinical stage of the tumor
[82].5. Reference values
Determination of A1M in human plasma or serum
is complicated by the presence of different forms of
the protein. Consequently, reports on normal A1M
concentrations in human plasma/serum have varied
widely especially since an international accepted stan-
dard is not available.
Table 3 summarizes some of the most important
existing data for the most widely used biological
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damage may help to improve the quality of the test
interpretation.References
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CHAPTER 4: Flow cytometric analysis 
 
As mentioned in the introduction, flow cytometric analysis of urine has gained wide 
acceptance in the last years. One instrument dedicated to this analysis is the UF-100 
(Sysmex, Kobe, Japan). 
Although originally developed for the analysis of urine, the same instrument was evaluated 
for analysis of other body fluids with an expected low cell count, e.g. cerebrospinal fluid 
(33), semen (35) and saliva (34). 
 
Instrument description (36) 
For identifying urine particles, the UF-100 flow cytometer combines flow cytometry with 
impedance analysis of urine particles after staining with two fluorescent dyes. 
From 9 µL of native urine, several particles are counted and identified: RBC, WBC, 
squamous epithelial cells (EC), hyaline casts, pathological (inclusional) casts, bacteria, 
yeast-like cells, spermatozoa, crystals and small round cells (SRC). The latter include 
mostly renal tubular cells and transitional epithelial cells but also macrophages, intestinal 
epithelial cells and other occasional cells of the same size. 
Results are displayed as scattergrams and histograms and numerical values are reported. 
Additionally the system provides a flag for RBC size distribution. 
It is important to note that the manufacturer of the UF-100 has made modifications to the 
detection algorithm for bacteria (37). The software used in our laboratory is the older 
version (version 00-12) in which dual categories exist for bacteria classification as bacteria 
are detected in two different measurement modes. Small bacteria are mainly detected in a 
high-sensitivity measuring mode and expressed as ‘‘H-BACT’’ counts while the ‘‘BACT’’ 
count category refers to larger bacteria or bacterial aggregates which are detected in the 
normal measuring mode like all other particles. The revised version ads the H-BACT 
particles to the BACT channel of the instrument hence generating one single result. This 
revised BACT count is approximately 20 times higher than the original BACT count. The 
system can thus be more sensitive to noise since thrombocytes and debris may account for 
false-positive bacterial counts. 
 
 In sampler operation mode, urine is automatically mixed, aspirated and diluted. The 
dilution buffer stabilizes the osmotic pressure of urine within a defined range thus enabling 
the impedance measurement. Tri-potassium ethylene diamine tetra-acetic acid (K3 -EDTA) 
chelates amorphous phosphates. 
 
 
 
Figure 2: Principle of urine flow cytometry (UF-100) 
 
This figure is presented in a publication by Delanghe et al (36). 
Signal generation in the Sysmex UF-100. As the sample passes through the flow cell, a 
laser beam encounters the particles and specific forward light scatter and fluorescence 
signals are emitted. The forward scatter intensity (Fsc), reflected in the height of the 
electronic signal, indicates the diameter of the particle, whereas the width of the forward 
scatter signal (Fscw) is related to the length of the particle. Likewise the fluorescence 
intensity indicates the stainability of the particle or a section thereof, and the fluorescence 
pulse width is related with the length of the stained area. Additionally the impedance 
signal, illustrating the cell volume, is detected. 
 
 
 
 
  
The sample is heated to 37°C to dissolve amorphous urates and, after staining with 
carbocyanine (to stain the cell membrane) and phenanthridine (to stain nucleic acids), 
enters the flow cell. The particles are hydrodynamically focused; an argon laser beam at 
wavelength 488 nm encounters these particles and particle-specific forward light scatter 
and fluorescence signals are emitted. Based on the characteristics of forward scatter (Fsc), 
forward scatter pulse width (Fscw), fluorescence (Fl), fluorescence pulse width (Flw) and 
impedance, the urine particles are classified. The UF-100 incorporates an extensive system 
of manufacturer-defined and user-definable review flags. Samples with particle counts 
exceeding clinical decision points can be flagged according to user-definable limits. 
Control on WBC and RBC count is carried out using latex particles supplied by the 
manufacturer. It is recommended that this material should be used once or twice daily for 
internal quality control purposes. 
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Abstract
Background. Recently, the Sysmex UF-100 ﬂow
cytometer has been developed to automate urinalysis.
We have evaluated this instrument to explore the
possibilities of ﬂow cytometry in the analysis of
peritoneal dialysis ﬂuid (PD) and have compared the
obtained data with those of counting chamber
techniques, biochemical analysis and bacterial culture.
Methods. UF-100 data were correlated with micro-
scopy and biochemical data in 135 PD samples. Micro-
biological analysis was performed in 63 suspected cases
of peritonitis.
Results. Good agreement (P<0.001) was obtained
between UF-100 and microscopy data for leukocytes
(r¼ 0.825). UF-100 bacterial count correlated
(P<0.001) with UF-100 leukocyte count (r¼ 0.549).
UF-100 bacterial counts were unreliable in samples
where interference by blood platelets was observed.
Another major problem was the UF-100 ‘bacterial’
background signal in sterile PD samples. Yeast cells
were detected by the ﬂow cytometer in spiked samples.
Conclusions. Flow cytometry of PD with the UF-100
offers a rapid and reliable leukocyte count. Sensitivity
of the ‘bacterial’ channel count in predicting positive
culture exceeds the sensitivity of conventional Gram
stain. Furthermore, additional semi-quantitative infor-
mation is provided regarding the presence of yeasts.
Keywords: ﬂow cytometry; infection; microorganisms;
peritoneal dialysis; UF-100
Introduction
Peritoneal dialysis (PD) is a widely accepted treatment
for end-stage renal disease [1,2]. Peritonitis, a frequent
and major complication of PD, is associated with high
risk of mortality and morbidity [3,4], is one of the most
frequent causes of peritoneal catheter loss and dis-
continuation of PD [5] and leads sometimes to a serious
complication like sclerosing peritonitis [6]. Peritonitis-
free dialysis remains an important goal for the long-
term use of the peritoneum as a dialytic membrane [7].
The diagnosis and effective treatment of peritonitis
depends on clinical evaluation and correlation with
laboratory examination of the dialysate. Diagnostic
criteria of peritonitis in PD patients include any two of
the following: cloudy or turbid efﬂuent containing
>100 leukocytes/ml, abdominal pain and a positive
ﬂuid culture [8,9]. Previous reports have demonstrated
problems associated with the diagnosis of peritonitis
based solely on these indicators [9]. Various techniques
have been used to facilitate the recovery of micro-
organisms from dialysate, among them the use of
selected broth media, processing of large volumes of
dialysis efﬂuent by concentration techniques or total
volume culture. Nevertheless, microorganisms are not
always recovered from dialysate during peritonitis
[10,11]. Numerous non-infectious causes of cloudy
peritoneal dialysate are known [12]. Fungal causes
should be ruled out as early as possible [12]. Other
markers have been described [13,14], sometimes not
being speciﬁc to peritonitis [14].
Microscopy has been the gold standard for counting
leukocytes [white blood cells (WBC)] in PD ﬂuid.
However, it is imprecise and has wide interobserver
variability. Moreover, it is labour-intensive and time
consuming. Automation seems the answer to improve
both accuracy and productivity of PD ﬂuid analysis.
A ﬂow cytometer-based instrument (UF-100) that
performs automated microscopic analysis has been
developed. Until now, this instrument has been
evaluated for urinalysis [15–17] and analysis of CSF
[18] and saliva [19]. Since ﬂow cytometry allows
accurate and precise quantitative analysis of cells, we
aimed to explore the possibilities of the instrument to
analyse PD ﬂuid. In this study, ﬂow cytometric data
from PD ﬂuid were not only compared with Fuchs-
Rosenthal chamber counting but also with biochemical
and microbiological data.
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De Pintelaan 185, B-9000 Ghent, Belgium. Email: joris.delanghe@
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Subjects and methods
Patients and samples
We studied 135 routinely collected PD ﬂuid samples.
Diagnosis of peritonitis could be suspected when symptoms
such as cloudy ﬂuid, fever, abdominal pain and rebound
tenderness were present. All samples consisted of a collection
in a sterile container for routine biochemical analysis and
an accompanying dialysis bag for bacteriological analysis.
We obtained samples from 13 (35%) male and 24 (65%)
female patients with an age distribution of 2–75 years
(median: 55 years) admitted to the renal division of the
University Hospital, Ghent. Suspected peritonitis was the
most important reason of admission. All analyses were
performed within 8 h after collection. The dialysis ﬂuids
contained NaCl (5.7 g/l), sodium lactate (3.9 g/l), CaCl2
(257mg/l), MgCl2 (152mg/l) and glucose (13.6, 22.7 and
38.6 g/l) with an osmolality range of 275–494 mOsm/l.
Sysmex UF-100
The Sysmex UF-100 (TOA Medical Electronics, Kobe,
Japan) uses argon laser ﬂow cytometry and measures the
sample conductivity. Particles are analysed by electrical
impedance for volume, forward light-scatter for size and by
ﬂuorescent dyes for DNA (phenanthridine) and membranes
(carbocyanine). Pulse intensity and pulse width of the
forward scattered light and ﬂuorescence light are measured.
From the data, together with the impedance data, the
formed particles are categorized by multi-parametric algo-
rithms on the basis of their size, shape, volume and staining
characteristics. The results are displayed in scattergrams,
histograms and as counts/ml. The UF-100, initially devel-
oped for urinalysis, automatically detects and counts
erythrocytes [red blood cells (RBC)], WBC, bacteria, yeast
cells, crystals, epithelial cells, small round cells, sperm cells
and casts. Particles that cannot be classiﬁed are counted as
‘other cells’.
Biochemical and microscopic investigations
Total PD ﬂuid protein concentration was measured using a
pyrogallol red assay (Sopachem, Brussels, Belgium) on a
Hitachi 917 analyser (Roche Diagnostics, Mannheim,
Germany). Manual microscopic examination of leukocytes
was performed in Fuchs-Rosenthal counting chambers. In
each sample at least 20 random microscopic ﬁelds were
examined at 40 10 magniﬁcation and the mean WBC cell
count was calculated.
Microbiological investigations
Handling of the injection ports and the ﬂuid exchange system
was according to standard hospital hygienic rules: injection
ports were disinfected with methanol and were allowed to dry
for 2min. Dialysate was then aspirated into a separate sterile
container and sent to the laboratory for routine chemical
investigation. Microbiological investigations were performed
in 63 samples (49%).
The dialysis ﬂuid bags were tested for the presence of
bacteria. Before adding brain–heart infusion broth (10 times
concentrated) for enrichment, two sterile tubes (50ml) were
sampled from this bag, centrifuged (1000 g, 10min) and the
sediment was inoculated to several media: 5% sheep blood
agar, chocolate agar, thioglyconate broth (with parafﬁn),
Schaedler agar (anaerobical incubation), Sabouraud agar,
Candida ID agar (Biomerieux) and tryptic soy agar with
incorporated Tween 80 for disruption of WBCs to obtain a
higher bacterial recovery. Identiﬁcation of isolates was by
standard bacteriological methods. The ﬂuid bags and all
cultures were incubated and examined daily for 7 days. This
way, most organisms are discovered with an easy to perform
method [10].
Gram stain was also performed on the sediment. Slides
were examined by light microscopy under immersion oil at
100 10 magniﬁcation.
Performance and interference studies
To evaluate the linearity in the UF-100 bacterial count
channel, we analysed isotonic saline solutions (5ml) contain-
ing one colony from patient isolates of Escherichia coli (n¼ 3)
and Streptococcus agalactiae (n¼ 3). Platelet-rich plasma,
obtained after centrifugation of sterile citrated blood for
10min at 200 g (n¼ 3; average platelet count: 485 103/ml),
was used to study suspected interference of platelets in the
bacterial count.
Three physiological saline solutions (5ml) containing one
colony of Cryptococcus neoformans were used to evaluate the
UF-100 yeast cell count.
Statistics
Data are presented as median and interquartile range (range
between 25th and 75th percentile). Agreement between
automated cell counts and microscopic data was examined
by Spearman rank analysis. Statistical signiﬁcance was
considered at the level of P<0.05. To assess the diagnostic
accuracy of WBC, bacteria and total protein, we used ROC-
curves and calculated the areas under curves (AUCs) for
comparison.
Results
Leukocytes and erythrocytes
The distributions of automated (UF-100) cell counts
in negative and positive cultures are summarized in
Table 1. Median overall UF-100WBC and RBC counts
were 7 WBC/ml (interquartile range: 4–32 WBC/ml) and
5 RBC/ml (interquartile range: 2–25 RBC/ml), respec-
tively. After logarithmic transformation, good agree-
ment (P<0.001) was found between UF-100 and
microscopic counts for WBC (r¼ 0.825) (Figure 1).
Bacteria
Median overall UF-100 count was 31 bacteria/ml
(interquartile range: 13–95 bacteria/ml). Similar to
UF-100 analysis of cerebrospinal ﬂuid, a ‘bacterial’
background signal was detected by the instrument
in PD ﬂuid samples with negative bacterial culture.
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Bacterial cultures were positive in 27 of 63 cultured
specimens (43%) and showed coagulase-negative sta-
phylococci (n¼ 5), Staphylococcus aureus (n¼ 5),
Streptococcus viridans (n¼ 3), Stenotrophomonas mal-
tophilia (n¼ 3), Corynebacterium sp. (n¼ 3), Candida
albicans (n¼ 1) and mixed infections (n¼ 7). Figure 2
represents the automated count in function of the
culture result. In contrast to the ﬂow cytometric data,
Gram stain followed by microscopy only allowed to
detect six of 27 positive cultures (22%).
A moderate correlation was found between the
bacterial and WBC counts on the ﬂow cytometer:
log(bact; bacterial count/ml)¼ 1.19 log(WBC; leuko-
cyte count/ml)þ 0.38 (r¼ 0.549; P<0.001) (Figure 3).
Epithelial cells
Epithelial cells are also measured by the UF-100. No
signiﬁcant difference was observed in epithelial cell
count between culture-positive and culture-negative
cases.
Yeast cells
In none of the samples, UF-100 yeast cell counts
were above the manufacturer-deﬁned cut-off value
(10 cells/ml). However, C.neoformans yeast cells were
correctly categorized by the UF-100 in three physio-
logical saline solutions to which one colony of
C.neoformans was added (mean yeast cell count:
28 cells/ml).
Interference studies
Interference studies focused on the UF-100 bacterial
count. In 58 of 64 (90.6%) samples with a bacterial
count above the 75th percentile, Gram stain and/or
culture remained negative.
We assumed possible interference of cell debris in
the UF-100 bacterial count. In diluted sterile K2EDTA
blood (1/100 to 1/1000) samples, UF-100 bacterial
counts were high (>100 bacteria/ml). Further analy-
sis of platelet-rich plasma (n¼ 3) showed that plate-
lets were exclusively categorized as bacteria by the
instrument.
ROC-curve analysis
Figure 4 represents a ROC-curve, based on UF-100
analysis, for early prediction of positive PD ﬂuid
culture.
Fig. 1. Correlation (line in full) between ﬂow cytometry (UF-100) and microscopy counts of WBC: log(microscopy WBC;
cells/ml)¼ 0.0067þ 0.97 log(ﬂow cytometry WBC; cells/ml) (r¼ 0.825; P<0.001). The dashed line indicates the ideal relationship.
Table 1. Distribution of automated (UF-100) RBC, WBC, bacterial, epithelial cell counts and total protein
Percentile Culture positive (n¼ 27) Culture negative (n¼ 33)
RBC
(/ml)
WBC
(/ml)
Bacteria
(/ml)
Epithelial
cells
(/ml)
Total
protein
(mg/dl)
RBC
(/ml)
WBC
(/ml)
Bacteria
(/ml)
Epithelial
cells
(/ml)
Total
protein
(mg/dl)
10 1 5 18 0 0.00 2 3 11 0 0.00
25 3 9 28 0 0.00 4 4 21 0 0.00
50 9 41 95 1 1.07 7 15 36 1 0.60
75 28 310 178 4 1.93 44 40 69 6 1.24
90 30 1367 290 9 2.67 520 267 229 11 1.81
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At a cut-off level of 58 WBC/ml, a sensitivity of
50.0% and speciﬁcity of 78.9% was observed. The
corresponding AUC was 0.655, which was slightly
better than the AUC for bacteria (0.634) and total
protein (0.605). Addition of other analytes (bacteria,
protein) in the model resulted in slightly improved
diagnostic performance with a sensitivity of 75.0%, a
speciﬁcity of 72.2% and an AUC of 0.743 (Figure 4).
Discussion
We have evaluated the use of a ﬂow cytometer (Sysmex
UF-100) in the routine analysis of PD ﬂuid. A good
agreement was obtained between WBC counts by the
UF-100 and the counting chamber. Comparison
with counting chamber techniques, the ‘gold standard’,
is difﬁcult as the latter technique has several steps
that may contribute to imprecision and inaccuracy.
Especially in the high WBC range, accuracy of
microscopic counting can be poor.
As the UF-100 has initially been developed for
urinalysis, ﬂow cytometric gating for the detection of
leukocytes is focused on the neutrophils, which pre-
dominate in peritonitis [10,20]. In most cases and
especially when low cell counts are encountered, ﬂow
cytometry offers a rapid and reliable WBC count. It
has been shown that neutrophils and monocytes are
properly classiﬁed as leukocytes [18].
Because the UF-100 also reports data on bacteria,
it might be tempting to use bacterial counts in report-
ing probabilities for peritonitis. However, two major
Fig. 3. Correlation between bacterial and WBC counts on the ﬂow cytometer: log(bact; bacterial count/ml)¼ 1.19 log(WBC; leukocyte
count/ml)þ 0.38 (r¼ 0.549; P<0.001).
Fig. 2. Box-and-whisker plots of automated UF-100 bacterial count in samples with positive and negative culture results.
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points of concern are involved. First, as was the case in
the analysis of cerebrospinal ﬂuid [18], a ‘noise’ was
detected in the bacterial channel, possibly representing
cell debris, which cannot be distinguished from
bacteria. This is a major concern for ﬂow cytometric
analysis of PD ﬂuid, as this body ﬂuid is sterile in
normal conditions. Secondly, this parameter has no
added value in distinguishing peritonitis because of the
wide spreading of the data (Figure 2).
Sensitivity and speciﬁcity of the bacterial count in
predicting culture were 43 and 77.8%, respectively,
which is better than the traditional Gram stain where
bacteria were only seen in 22% of positive cultures, a
ﬁgure which is comparable with previous publications
[10,20]. This illustrates the difﬁculties in culturing PD
ﬂuid: the concentration of bacteria is usually low and
there is the possibility of pathogens located in the white
blood cells [10].
In vitro supplementation of PD ﬂuid with peripheral
blood resulted in a small apparent increase in the
bacterial channel count despite negative Gram stain
and culture. We postulate that interfering particles
(probably cell fragments) are measured in the bacterial
channel. Cell fragments and bacteria share similar
ﬂow cytometric characteristics (low forward scatter,
low phenanthridine and carbocyanine ﬂuorescence).
Moreover, we demonstrated that blood platelets are
exclusively categorized as ‘bacteria’ by the UF-100.
The additional capacity of the UF-100 to detect
yeasts was demonstrated in spiked samples and might
help the clinician in the early diagnosis of peritonitis
caused by yeasts [12].
In conclusion, ﬂow cytometric analysis is a useful
additional tool for PD examination, especially in the
emergency setting. It provides rapid (36 s) and accurate
data on WBC content of PD ﬂuid. The apparent
bacterial count is more sensitive than the conventional
Gram stain in predicting positive bacterial cultures and
results of bacterial channel count and total protein only
have small additional value in the ROC-curve analysis.
Absolute ﬂow cytometric bacterial counts should be
interpreted with caution since they do not solely
represent bacteria. The background ‘bacterial’ signal
in sterile PD ﬂuid is a major point of concern. The
possibility to detect yeast cells in spiked samples,
suggests that the instrument might help in the diagnosis
of fungal peritonitis.
Conﬂict of interest statement. None declared.
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Abstract 
Background: Urinalysis comprises three techniques: urinary flow cytometry, test strip 
analysis and determination of specific urinary proteins. We have investigated the 
diagnostic possibilities of combining these methods in a cohort of well-documented 
patients presenting with a broad variety of nephrological and urological conditions. 
Methods: Urinary samples of 407 in- and outpatients with nephrological or urological 
pathology were retrospectively included in our study. Test strip analysis (URISYS 2400), 
urinary flow cytometry (UF-100) and urinary protein analysis (albumin, total protein, alpha 
1-microglobulin (A1M), alpha 2-macroglobulin (A2M)) had been carried out. 
Results: In discriminating upper and lower urinary tract infections, A1M and 
A1M/log(white blood cells) can be used but pathological casts only gives a poor 
discrimination. The ratio A2M/log(RBC) allows differentiation between cystitis and 
pyelonephritis while glomerular diseases can be recognised by the log(RBC x urinary total 
protein). Combining A2M and urinary albumin allows the determination of acute 
prostatitis. 
Conclusions: By using combined parameters provided by various techniques, ratios can be 
proposed that may be helpful in classifying renal and urological conditions. Possible 
integration in computer-based knowledge systems may offer valuable information for 
clinicians. 
 
 
 
  
Introduction 
The field of urinalysis has thoroughly been changed by the advent of some new diagnostic 
techniques. The introduction of urinary flow cytometry (1), (semi) quantitative test strip 
reading (2) and specific urinary protein analysis (3;4) all have created new diagnostic 
possibilities. A better analytical precision (5), and a more refined diagnosis (4) have been 
associated with these new techniques. From a relatively simple basic data set, a number of 
clinically useful conclusions can be drawn (e.g. selectivity of glomerular membrane 
defects, differentiation of hematuria, localisation of urinary tract infection). However, the 
amount of diagnostic information needed for this advanced medical decision making is 
critical. This has been a major threshold for the introduction of these techniques into 
routine clinical practice. Recently, a number of attempts have been made to use 
knowledge-based systems to improve diagnostic decision making (1;4). The majority of 
the clinical studies involved have been mainly limited to nephrological cases. However, 
also in urological conditions, the use of specific proteins was shown to be very promising 
especially in the location of urinary tract infection, the staging of vesico-ureteral reflux and 
the diagnosis of prostatitis (6;7). 
Alpha 1-microglobulin (A1M) is a 27 kDa glycoprotein which is a marker for evaluation of 
tubular function. Because A1M is not an acute phase protein (its concentration being 
unaffected by inflammatory reactions) and since it is stable in a broad range of 
physiological conditions (8), its measurement can be used for clinical purposes. Urinary 
A1M provides a non-invasive, inexpensive diagnostic alternative for the diagnosis and 
monitoring of urinary tract disorders (eg. early detection of tubular disorders such as heavy 
metal intoxications, diabetic nephropathy, urinary outflow disorders and pyelonephritis) 
(8). Computer-assisted interpretation of parameter sets including A1M as marker for 
tubular damage may help to improve the quality of the test interpretation. 
Alpha 2-macroglobulin is a plasma protein (725 kDa) functioning as a broad-spectrum 
protease-binding protein (e.g. alpha 2-chymotrypsin, prostate specific antigen). This 
protein appears in the urine in post-renal hematuria as well as in urinary tract infection 
(7;9). 
 
Flow cytometry has been introduced for urinalysis (10;11) to obtain quantitative data on 
urinary particles. The imprecision of urinary flow cytometry is far less than that of 
conventional urinary microscopy. Combining diagnostic information provided by urinary 
  
flow cytometry and quantitative test strip analysis therefore offers a theoretical basis for 
the development of diagnostic expert systems (1;12). 
In this study we have explored the diagnostic possibilities of combining urinary flow 
cytometry, test strip reading and the determination of specific urinary proteins (alpha 1-
microglobulin and alpha 2-macroglobulin) in a cohort of well-documented patients 
presenting with a broad variety of nephrological and urological conditions. 
 
 
Materials and Methods 
Patients and samples 
A large database was created containing data of freshly collected urine samples submitted 
to our routine laboratory for diagnostic urinalysis. All samples were received from the 
nephrology and urology departments involving 637 inpatients and 371 outpatients 
(n=1008) with an age distribution of 16-83 years (median: 41 years). Samples were 
completely processed within 2–4 h after arrival. Test strip urinalysis was carried out before 
flow cytometry analysis (Sysmex UF-100; TOA Medical Electronics, Kobe, Japan) on a 
URISYS 2400 analyzer (Roche Diagnostics, Mannheim, Germany). 
Medical records were retrospectively examined for diagnoses concerning nephrological or 
urological pathologies resulting in 407 proven diagnoses: glomerulonephritis (n = 17), 
glomerular diseases (n = 59), pyelonephritis (n = 46), cystitis (n = 257), prostatitis (n = 10), 
uncomplicated renal calculi (n = 8), uncomplicated/unexplained hematuria (n = 5) and 
polycystic disease (n = 5). The classification mentioned was made on the basis of expert 
opinion. 
Urinary flow cytometry and test strip reading was carried out on all samples. 
 
Urinary flow cytometry 
The Sysmex UF-100 is a urinary flow cytometer-based walkaway instrument that performs 
automated microscopic analysis. It has been extensively evaluated for urinalysis (1;10;11). 
The principle is based on argon laser flow cytometry. The UF-100 measures the 
conductivity and categorizes the particles on the basis of their shape, size, volume, and 
staining characteristics. The results are displayed in scattergrams, histograms, and as 
counts per microliter as well as counts per high-power field. The UF-100 automatically 
detects and counts red blood cells (RBCs), white blood cells (WBCs), bacteria, yeast cells, 
  
crystals, epithelial cells, small round cells (this category includes renal tubular cells and 
transitional epithelial cells) (5), sperm cells and casts. Particles that cannot be classified in 
one of the former categories are counted as "other cells". 
 
URISYS 2400 
Urine test strip analysis was performed with the automated URISYS 2400. The intensity of 
the reaction colour of the test pad is detected by measuring the percentage of light, which 
is reflected from the surface to the test pad. A higher analyte concentration results in a 
higher colour intensity thus in a lower reflectance value. The reflectance value, expressed 
as "%" within a range from 100% (white) to 0% (black), is therefore inversely to the 
concentration of the analyte in the sample. Data are expressed in an ordinal scale (as 
“normal”, “negative”, “positive” or as nominal concentrations). 
  Specific gravity (refractometry based) and clarity are measured in a flow cell and colour 
is rated with a specific algorithm against the blank pad on the test strip.  
 
Biochemical investigations 
Urinary albumin was measured immunonephelometrically on 389 samples with use of 
commercially available Behring antibodies on a Behring Nephelometer II analyzer (Dade 
Behring) standardized against the widely accepted WHO/College of American Pathologists 
Certified Reference Material 470. 
Total protein was performed on all samples by a pyrogallol red method (13) with Standard 
Reference Material 917a as a standard on a Modular P system (Roche Diagnostics, 
Mannheim, Germany). Urinary A1M (n=393) was determined on a Roche Modular P 
System (Roche Diagnostics, Mannheim, Germany). A2M in urine (n=378) was measured 
immunonephelometrically on a BNII nephelometer (Dade Behring, Marburg, Germany). 
 
Statistics 
P values <0.05 were considered significant. Differences between patient groups were 
evaluated using one-way ANOVA. Diagnostic accuracy was assessed by ROC analysis. 
All statistical calculations were performed using commercially available statistical software 
(MedCalc®, Mariakerke, Belgium). 
 
  
Results 
To evaluate preservation conditions of the urine sample tested, the bacteria/WBC ratio can 
be used for the detection of pre-analytical errors, which is an important issue in urinalysis 
(12). Stale urine samples are characterized by a high bact/WBC ratio (1). 
Since A1M and WBC are disturbed in different pathological situations and their 
concentration is influenced by different factors, combining the two parameters could be 
used to differentiate several pathologies. The information contained by both A1M and 
WBC parameters was expressed as the urinary A1M/log(WBC) ratio. Figure 1 compares 
the A1M/log(WBC) ratio in urinary tract infections according to their anatomical 
localisation. Lower and upper urinary tract infections show marked differences in their 
A1M concentration and A1M/log(WBC) ratio (P<0.001). 
Figure 2 pictures the ROC curves of several parameters for disciminating upper from lower 
urinary tract infections. The parameters mostly used are pathological casts and WBC with 
which we compared A1M and the A1M/log(WBC) ratio. The pathological cast count only 
gives a poor discrimination between the two anatomical localisations (AUC = 0.522; 
sensitivity = 69.4%; specificity = 39.3%), whereas A1M showed the highest area under 
curve (AUC = 0.955; sensitivity = 97.1%; specificity = 92.2%). 
Figure 3 depicts the diagnostic possibilities of combining the data of urinary A1M and 
leukocytes to localise the urinary tract infection. Four quadrants can be defined by drawing 
two perpendicular cut-off lines at respectively 25 WBC/µL and 10 mg/L for A1M (5) to 
classify the pathological cases. The lower left quadrant corresponds to non-pathological 
cases, the upper left is associated with non-infectious tubular pathology (e.g. heavy metal 
intoxication), the upper right quadrant contains the upper UTI cases and the lower right 
quadrant the lower UTI patients. 
Table 1 represents the discriminative power with matching sensitivity and specificity for 
several possible parameters in discriminating upper from lower urinary tract infections in 
cases with significant leucocyturia (WBC>25/µl). These parameters include A1M, WBC, 
A1M/log(WBC), pathological casts, hyaline casts and small round cells (this category 
comprises renal tubular cells and transitional epithelial cells) (5). 
The urinary A2M values (a biochemical marker for postrenal bleeding) are plotted against 
the log-transformed urinary RBC count in figure 4 showing the independency of both 
parameters. The effect representing in this figure as a gap, is due to measurements below 
the cut-off. Values for alpha 2-macroglobulin above the cut-off are typical for cases of 
post-renal bleeding, a fact that is inherent to the large molecular weight of the protein. As 
  
expected, no significant correlation can be found. In the patients presenting with significant 
hematuria (urinary RBC count >25 cells/µL), a further clinical analysis was made 
according to the anatomical localization of the hematuria. Figure 5 depicts the urinary 
A2M/log(RBC) ratio in the specific conditions of cystitis, prostatitis and pyelonephritis. A 
significant difference between two conditions was seen with a median of 0.64 [interquartile 
range: 0.51 – 1.89] and 1.59 [interquartile range: 0.51 – 3.82] for cystitis and 
pyelonephritis respectively (P<0.05) while prostatitis could not be distinguished from 
either of the former groups. 
Since urinary A2M determinations are not carried out in the majority of clinical 
laboratories on a routine basis, alternatively total urinary protein was used as a substitute 
parameter. 
To separate glomerular versus non-glomerular disease, the parameter log(RBC x urinary 
total protein) could be used as shown in figure 6. Glomerular diseases are characterised by 
hematuria (increased RBC counts) and proteinuria. However, the specificity of both 
parameters is subject to improvement. Therefore, by combining the two parameters in one 
formula by using the product, a better discriminatory power can be obtained, increasing the 
diagnostic power of the variables. In glomerular disease, a significantly higher value is 
found: 118.49 [interquartile range: 40.90 – 504.58] vs. 32.12 [interquartile range: 11.03 – 
111.76] for glomerular and non-glomerular disease respectively (P<0.05). 
Using the fraction A2M/urinary albumin, acute prostatitis could be differentiated from 
other pathologies: 0.06 [interquartile range: 0.04 – 0.16] vs. 0.03 [interquartile range: 0.02 
– 0.05] for acute prostatitis and other hemoglobinurias respectively (P<0.05). 
Finally, the effect of the urinary concentration, as expressed by the conductivity and the 
specific gravity, on the most important analytes was checked. No significant affect was 
seen on WBC, RBC, A1M, A2M and bacteria. 
 
 
Discussion  
Alpha 1-microglobin is a well-known tubular protein which can be raised in both 
infectious and non-infectious conditions (8) offering an interesting alternative for 
evaluating tubular function. It passes through the glomerulus out into the primary urine, 
from which it is reabsorbed by the proximal tubules where catabolization occurs (14). 
  
On the other hand, leukocyturia, which can be determined in an accurate way (10;11;15), is 
a good indicator of UTI but unfortunately does not discriminate between upper and lower 
tract UTI. 
In the present study, A1M proved to be a useful discriminator between upper and lower 
urinary tract infections. This observation is in correlation with a previous report of 
proximal tubular damage in urinary tract infection in children (16). When using the 
combined information of A1M and leukocytes as in the form of A1M/log(WBC), no 
improvement was seen in the sensitivity or specificity, indicating that A1M on itself makes 
a discrimation possible between upper and lower urinary tract infections in cases of 
increased leukocyturia. However, by using the combined information provided by A1M 
and WBC, four quadrants can be defined being non-infectious tubular pathology, upper 
and lower urinary tract infections and a quadrant containing other urinary tract pathology 
not involving WBC or A1M excretion. This classification can be helpful in diagnosing 
tubular and infectious urinary pathology. It must be remarked however that since non-
infectious tubular pathology, like heavy metal intoxication, is very rare in our region, no 
cases could be included in our patient groups so this quadrant represents the part in which 
theoretically these patients should present. 
Traditionally the presence of white blood cell casts on the examination of the urinary 
sediment has been assumed to be highly specific for and pathognomic of upper urinary 
tract infection, leading to pursue an aggressive course of therapy (17). However, we found 
that both casts, reported as hyaline or pathological casts, and small round cells, as 
measured by the UF-100 flow cytometer, showed a low specificity for localizing urinary 
tract infection. The poor diagnostic information provided by the flow-cytometrically 
determined cast counts can be attributed to the low number of casts usually found and the 
difficult quantification of these urinary structures, not only by flow cytometry (5;15;18). 
A1M has the advantage of being a stable protein that can be measured on routine clinical 
chemistry analyzers hence giving rise to low imprecision and high reproducibility (8). This 
offers advantages over the counting of casts which are more brittle and subjects to greater 
inter-observer variability. 
 
For the evaluation of significant hematuria (RBC>25 cells/µL), another specific protein 
(alpha 2-macroglobulin; A2M) as a marker for postrenal bleeding can be used. Since it is 
not related to or dependent of the urinary RBC-concentration, A2M can provide additional 
information in hematuria cases. Cystitis and pylonephritis can be distinguished and by 
combining A2M with urinary albumin concentrations, prostatitis cases can be identified, in 
  
concordance with previous results (7). Since A2M is not a routine parameter in most 
laboratories, other possible combinations for classifying glomerular disease were 
investigated. By using log(RBC x urinary total protein), glomerular disease can be 
separated from other diseases. Although the difference between the two conditions is 
statistically significant, there still is an overlap zone between the two conditions, as can be 
seen in figure 6. It should be noted, however, that a log-scale is used to present the data 
which can give the impression that the medians do not differ a lot while in reality they can 
differ up to 5 times. Secondly, this still is better then the present situation (e.g. use of casts) 
giving rise to much worse possibilities in differentiation. 
 
In agreement with earlier observations by Langlois et al, the bacteria/WBC ratio can be 
used for the detection of pre-analytical errors, which is an important issue in urinalysis 
(12). Stale urine samples are characterized by a high bact/WBC ratio (1). 
 
 
Conclusions 
Urinalysis has evolved into the modern age of measuring. Flow cytometry has improved 
the accuracy of the analysis of the urine sediment while test strip analysis plays an 
important role in urinalysis as such, and the value of test strip urinalysis as a screening 
method has been thoroughly demonstrated (19). Measurement of specific and stable 
proteins like albumin, A1M and A2M provide additional information about the renal and 
urological function and structure. When these data can be combined, using a relatively 
simple data set can provide an extra amount of useful clinical information by integrating 
results from various new urinalysis techniques (urinary flow cytometry, specific urinary 
protein analysis, test strip reading). 
The proposed ratios of this study can easily be implemented in a Laboratory Information 
System (LIS). Furthermore, they can be useful for providing additional diagnostic 
information when implemented in computer knowledge-based expert systems (9;20;21). 
 Tables 
Table 1: Comparison of the discriminative power of several parameters for upper versus 
lower urinary tract infections for all cases with significant leukocyturia (WBC>25/µL) 
parameter criterion sensitivity specificity AUC 
A1M/log(WBC) 4.20 94.1 86.3 0.943 
A1M 10.6 mg/L 97.1 92.2 0.955 
WBC 230 WBC/µL 67.3 50.2 0.574 
Hyaline casts 0.1 casts/µL 51,0 67,7 0.543 
Pathological casts 0 casts/µL 69.4 39.3 0.522 
Small round cells 0.8 cells/µL 81.6 37.3 0.593 
 
Figures 
Figure 1: Discrimination between low UTI versus upper UTI and prostatitis 
Box-and-whisker plots representing median and 25%/75% percentiles. 
Square markers indicate values larger than the upper quartile plus 1.5 times the 
interquartile range. Round markers indicate values larger than the upper quartile plus 3 
times the interquartile range. 
* indicates a statistically significant difference (p<0.05) with the other patient groups. 
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 Figure 2: Comparative discriminative power in the localisation of urinary tract infections 
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Figure 3: Combining urinary A1M- and leukocyte-data for localising urinary tract infection 
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 Figure 4: Urinary A2M versus RBC count in hematuria cases (for RBC counts > 25/µL) 
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Figure 5: Differentiation of pathology in cases of hematuria (for RBC counts > 25/µL) 
Values with a square marker are larger than the upper quartile plus 1.5 times the 
interquartile range. Values with a round marker are larger than the upper quartile plus 3 
times the interquartile range. 
* indicates a statistically significant difference (p<0.05) between the two marked groups. 
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 Figure 6: Differentiation of glomerular and non-glomerular pathology 
Values with a square marker are larger than the upper quartile plus 1.5 times the 
interquartile range. 
* indicates a statistically significant difference (p<0.05) with the other patient group. 
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CHAPTER 6: General discussion & future perspectives 
 
General discussion 
Using urine as the sample matrix for analyzing certain analytes does offer some specific 
peculiarities. It has the advantage of being obtainable in a painless, non-invasive manner; 
re-sampling is easy and urine is available in sufficient amounts. 
However, certain pitfalls and limitations do exist. Urine is not only very easily tampered 
with by adding additives that disturb measurements or by simply replacing it with a sample 
from another subject, also the physical properties (pH, specific gravity) may vary 
significantly resulting in instability of certain parameters. For example, RBC-morphology 
will be altered in diluted or concentrated urine, RBC and WBC may be destroyed in diluted 
urine, brittle structures like casts are unstable in alkaline urine, some specific proteins will 
be degraded in an acid or alkaline urine. Nephrotoxic medications like chemotherapeutics 
and aminoglycosides will influence the physical properties of the renal glomeruli and 
tubuli. This contributes to the uncertainty of measurements and the spreading of results. 
That is the reason why there has been strived for including a large number of patients in 
the study involved. This should compensate the effect mentioned. Moreover, intra-
individual variation is an equally important issue and may exert an effect that is as large as 
the effect of drugs. 
Also prelevation is an important issue especially when bacteriological examinations and 
(therapeutic) conclusions are to be involved. Therefore specific guidelines for urine 
sampling have been developed (38). 
 
It is clear, from the literature and from this thesis, that urinalysis has come a long way 
since the last fifteen to twenty years. The introduction of urinary flow cytometry made 
urinalysis a more standardised, quicker and less inter-observer dependent technique. 
The modern techniques can be used for more than urine analysis alone. The list of body 
fluids (apart from blood) that have been evaluated on flow cytometry, especially on 
analyzers developed for urine analysis, now comprises semen (35), saliva (34), 
cerebrospinal fluid (33) and CAPD (39). Specifically for CAPD, flow cytometric analysis 
seems to be a useful additional tool for its examination, especially in the emergency setting 
since it provides rapid and accurate data on WBC content of CAPD fluid. The apparent 
bacterial count is more sensitive than the conventional Gram stain in predicting positive 
  
bacterial cultures and results of bacterial channel count and total protein only have small 
additional value in the ROC-curve analysis. Of course, as in almost every technique, there 
are certain pitfalls so experience in interpreting these techniques is absolutely necessary. 
As in urine, absolute flow cytometric bacterial counts in PD fluid should be interpreted 
with caution since they do not solely represent bacteria but may be interfered by cellular 
debris. This background ‘bacterial’ signal in sterile PD fluid is a major point of concern. 
On the other hand, the possibility to detect yeast cells in spiked samples, suggests that the 
instrument can help in the diagnosis of fungal peritonitis. 
 
The possibilities of the automated urine test strip reading technology have been underused 
until recently. Not only can it be used in its classical ordinal scaled reading to improve the 
diagnostic performances of the urine flow cytometer (21), but since the quantitative 
reflectance reading of a test strip provides reliable data on WBCs, RBCs, glucose and 
albumin (40) it can also offer the possibility to a more fine-tuned expert system especially 
to improve the elimination of occasional errors in the WBC and RBC counting channels. 
 
More advanced applications of urine test strips in specific patient groups are emerging. We 
have shown that in diabetic patients, quantitative urine test strip analysis can provide 
reliable data on ketone body excretion (41). Quantitative reflectance analysis of the ketone 
test pad offers a simple and cheap method, well suited for the routine clinical laboratory 
that can be used in an emergency setting. Test strips show a high sensitivity for ketones 
allowing screening for ketone production in diabetes. In particular, the analysis allows 
monitoring of the metabolic state of diabetics on insulin pump treatment. Additional 
sample treatment with 3HB dehydrogenase allows the analysis of 3HB, which yields a 
more complete picture. 
 
To increase the diagnostic yield of urinalysis, specific proteins were introduced in the 
analysis perspectives of this field. A1M seems to become one of the most important 
analytes in nephrological en urological diagnostics (15-17;19;20;42;43) because of its 
stability in urine. It is an immunosuppressive protein with an unknown exact biological 
function. Many unusual and intriguing properties of the protein have been revealed. The 
protein acts as a mediator of bacterial adhesion to polymer surfaces and may play a role in 
renal lithogenesis. In the clinical laboratory, sensitive immunoassays allow us to use A1M 
determination for clinical purposes. Assaying urinary A1M provides a non-invasive 
inexpensive diagnostic alternative for the diagnosis and monitoring of urinary tract 
  
disorders (early detection of tubular disorders such as heavy metal intoxications, diabetic 
nephropathy, urinary outflow disorders and pyelonephritis). 
 
By developing expert systems, the diagnostic information contained in data that are not 
always easy to interpret will become more accessible also to non-experts. Diagnosis can be 
suggested and the work-out of the patient’s condition could become easier. Such a system, 
called UPES (29;44), was developed in a nephrological setting. We have integrated results 
from various urinalysis techniques like flow cytometry, test strip screening and specific 
urinary protein analysis, and by using a relatively simple data set one can provide an extra 
amount of useful clinical information. The proposed ratios of our final study can easily be 
implemented in a Laboratory Information System (LIS) and can be useful for providing 
additional diagnostic information when implemented in computer knowledge-based expert 
systems. 
 
Future perspectives 
Nowadays, test strips do not play the diagnostic role they could achieve. They are still 
regarded as an ancient, surpassed technique. However, they are not only cheap and fairly 
stable, they can also be used in a better way as we showed that their limit of detection for 
protein is much better than was presumed. Also the relation with flow cytometric RBC and 
WBC counts and with routine chemical glucose measurements is fairly good. This opens 
perspectives towards easily accessible screening data: the sensitivity for albumin may 
allow affordable screening for microalbuminuria, particularly in patients with undiagnosed 
renal damage. Large-scale global population screening has been the goal of the KDIGO 
(Kidney Disease Improving Global Outcomes) project of National Kidney Foundation 
(45). The analytes involved in these guidelines are albumin and creatinine. 
Our findings could be important on a large-scale population level in which the increasing 
incidence of hypertension and diabetes projects increasing renal disease. Early recognition 
of renal damage by means of screening for microalbuminuria is very important in these 
patient groups (46-49) and urine test strips may offer a cheap screening although a formal 
study should be performed to fully explore the possibilities of the albumin test pad in first-
line diagnosis. 
The aim of the classical multiple test strip is to perform routine chemical analysis in one 
single operation, yielding maximum diagnostic and prognostic information. Therefore, 
experts state that a maximum of 10 test areas should not be exceeded and re-evaluated the 
  
usefulness of the existing test pads (50). Indeed, some tests are now obsolete: one could 
argue about the (diagnostic) usability of bilirubin and urobilinogen on urine test strips. 
Some experts doubt the usability of the pH test pad although many prefer to keep this to 
guard the quality of the sample, to identify amorphous sediments and recognise false 
positive protein tests and cellular lysis. Therefore, some suggest to replace these with test 
pads that can add diagnostic validity to urine diagnostics. Attempts should be made to 
expand the use of test strips to more specific and useable analytes like A1M or others that 
proof to be useful after evaluation (51). 
It should also be noted that urine test strips do not allow the detection of Bence-Jones 
proteinuria. Despite the fact that Bence-Jones proteinuria usually does not present without 
being associated with proteinuria, this has to be taken into account when judging the 
results of the protein test pad. This test pad may be an object for future improvements of 
urine test strips since the only alternatives now are urine electrophoresis and/or immuno-
electrophoresis. 
 
Expert systems will become more refined and their use will extend further than the 
optimization of technical information. On the one hand, one can use them to overcome 
certain drawbacks of the techniques used (e.g. difficult differentiation between RBC and 
yeasts by flow cytometry, false positive reading of the hemoglobin pad by myoglobin in 
test strips, etc.). On the other spectrum, expert systems could develop to become of better 
assistance in diagnosing urological and nephrological diseases. 
Web-based access to expert systems on a central server would certainly contribute to the 
expansion of knowledge of urinalysis and expertise could be shared with non-experts. One 
could dream about kidney biopsies becoming redundant but they will probably always be 
needed for certain indications, for example in detecting immune complexes. 
The application of specific proteins in the diagnostic strategies for renal disease will not 
become a total substitute for kidney biopsy but it will offer an additional tool for gaining 
diagnostic information in a quick and especially painless way. 
 
Another important gap that still exists is the fact that we need more and better markers for 
diagnosing cancer of the bladder, kidneys and the prostate. These can possibly be found in 
urine by PCR based techniques, as shown by recent literature (52). 
Another idea could be to look at the surface of cells present in urine and check for certain 
expression profiles or certain CD-markers. Therefore, a free channel on the standard flow 
cytometric appliances can be of great help. 
  
REFERENCES 
 
1.  Poulakou-Rebelakou E. Aretaeus on the kidney and urinary tract diseases. Am J 
Nephrol 1997;17:209-13. 
2.  Guder WG, Kutter D, Bonin P. From uroscopy to molecular analysis - improving 
diagnostic information from urine analysis. Clinica Chimica Acta 2000;297:1-3. 
3.  Voswinckel P. From uroscopy to urinalysis. Clinica Chimica Acta 2000;297:5-16. 
4.  Free AH, Adams EC, Kercher ML, Free HM, Cook MH. Simple specific test for 
urine glucose. Clin Chem 1957;3:163-8. 
5.  Free AH, Rupe CO, Metzler I. Studies with a new colorimetric test for proteinuria. 
Clin Chem 1957;3:716-27. 
6.  Pugia M, Newman DJ, Lott JA, D'Mello L, Clark L, Profitt JA, Cast T. Detection of 
low-molecular-weight proteins in urine by dipsticks. Clinica Chimica Acta 
2002;326:177-83. 
7.  Jung K, Pergande M, Priem F, Becker S, Klotzek S. Rapid screening of low 
molecular mass proteinuria: evaluation of the first immunochemical test strip for the 
detection of alpha-1-microglobulin in urine. Eur J Clin Chem Clin Biochem 
1993;31:683-7. 
8.  Fogazzi G, Cameron JS. The introduction of urine microscopy into clinical practice. 
Nephrol Dial Transplant 1995;9:410-3. 
9.  Hughes C, Roebuck MJ. Evaluation of the IRIS 939 UDx flow microscope as a 
screening system for urinary tract infection. J Clin Pathol 2003;56:844-9. 
10.  Deindoerfer, F. H., Gangwer, J. R., Laird, C. W., and Ringold, R. R. "The Yellow 
IRIS" Urinalysis Workstation-The first commercial application of "Automated 
Intelligent Microscopy". Clinical Chemistry 31[9], 1491-1499. 1985.  
11.  Nakayama, A., Ishii, T., Jaekel, S., and Blaseio, U. The new automated bacteria 
analyzer Bacsys-40i. Sysmex J Int 13, 43-47. 2003.  
12.  Okada, H., Sakai, Y., Kawabata, G., Fujisawa, M., Arakawa, S., Hamaguchi, Y., and 
Kamidono, S. Automated urinalysis. Evaluation of the Sysmex UF-50. Am J Clin 
Pathol 115[4], 605-610. 2001.  
13.  Steinmetz, J., Henny, J., and Gueguen, R. Reference limits for urine sediments 
performed on Sysmex UF-50. Ann Biol Clin (Paris) 62[6], 671-680. 2004.  
  
14.  Wah DT, Wises PK, Butch AW. Analytic performance of the iQ200 automated urine 
microscopy analyzer and comparison with manual counts using Fuchs-Rosenthal cell 
chambers. Am J Clin Pathol 2005;123:290-6. 
15.  Everaert K, Raes A, Hoebeke P, Samijn W, Delanghe J, Vande Wiele C, Vande 
Walle J. Combined use of urinary alpha1-microglobulin and 99Tc DMSA 
scintigraphy in the diagnosis and follow-up of acute pyelonephritis and cystitis in 
children. Eur Urol 1998;34:486-91. 
16.  Everaert K, Delanghe J, Vande Wiele C, Hoebeke P, Dierickx RA, Clarysse B et al. 
Urinary alpha 1-microglobulin detects uropathy. A prospective study in 483 urolgical 
patients. Clin Chem Lab Med 1998;36:309-15. 
17.  Everaert K, Oostra C, Delanghe J, Vande Walle J, Van Laere M, Oosterlinck W. 
Diagnosis and localization of a complicated urinary tract infection in neurogenic 
bladder disease by tubular proteinuria and serum prostate specific antigen. Spinal 
Cord 1998;36:33-8. 
18.  Everaert K, Hoebeke P, Delanghe J. A review on urinary proteins in outflow disease 
of the upper urinary tract. Clin Chim Acta 2000;297:183-9. 
19.  Everaert K, Van Laecke E, Dekuyper P, Hoebeke P, Delanghe J, Oosterlinck W, 
Vande Walle J. Impact of urinary tract infection and detrusor pressure on renal 
tubular function in patients with vesicoureteral reflux. Eur Urol 2001;39:337-42. 
20.  Everaert K, Delanghe J, Vanderkelen M, Cornelis K, De Wachter S, Viaene A et al. 
Urinary plasma protein patterns in acute prostatitis. Clin Chem Lab Med 2003;41:79-
84. 
21.  Langlois M, Delanghe JR, Steyaert S, Everaert K, De Buyzere M. Automated flow 
cytometry compared with an automated dipstick reader for urinalysis. Clin Chem 
1999;45:118-22. 
22.  Everaert K, Hoebeke P, Delanghe J. A review on urinary proteins in outflow disease 
of the upper urinary tract 
22. Clinica Chimica Acta 2000;297:183-9. 
23.  Bernard, A. Renal dysfunction induced by cadmium: biomarkers of critical effects. 
Biometals 17[5], 519-523. 2004.  
24.  Uslu, S., Efe, B., Alatas, O., Kebapçi, N., Colak, O., Demirüstü, C., and Yörük, A. 
Serum cystatin C and urinary enzymes as screening markers of renal dysfunction in 
diabetic patients. J Nephrol 18, 559-567. 2005.  
25.  Akesson, A., Lundh, T., Vahter, M., Bjellerup, P., Lidfeldt, J., Nerbrand, C., 
Samsioe, G., Strömberg, U., and Skerfving, S. Tubular and glomerular kidney effects 
  
in Swedih women with low environmental cadmium exposure. Environ Health 
Perspect 113, 1627-1631. 2005.  
26.  Hofmann W, Rossmüller B, Guder WG, Edel HH. A new strategy for characterizing 
proteinuria and haematuria from a single pattern of defined proteins in urine. Eur J 
Clin Chem Clin Biochem 1992;30:707-12. 
27.  Guder WG, Hofmann W. Differentiation of proteinuria and haematuria by single 
protein analysis in urine. Clin Biochem 1993;26:277-82. 
28.  Ivandic M, Hofmann W, Guder WG. Development and evaluation of a urine protein 
expert system. Clinical Chemistry 1996;42:1214-22. 
29.  Lun A, Ivandic M, Priem F, Filler G, Kirschstein M, ehrich JH, Guder WG. 
Evaluation of pediatric nephropathies by a computerized Urine Protein Expert 
System (UPES). Pediatr Nephrol 1999;13:900-6. 
30.  Ivandic M, Hofmann W, Guder WG. The use of knowledge-based systems to 
improve medical knowledge about urine analysis. Clin Chim Acta 2000;297:251-60. 
31.  Ivandic M, Ogurol Y, Hofmann W, Guder WG. From a urinalysis strategy to an 
evaluated urine protein expert system. Methods Inf Med 2000;39:93-8. 
32.  Van Hoof, V., Wormek, A., Schleutermann, S., Schumacher, T., Lothaire, O., and 
Trendelenburg, C. Medical expert systems developed in j.MD, a Java based expert 
system shell: application in clinical laboratories. Medinfo 11, 89-93. 2004.  
33.  Van Acker JT, Delanghe JR, Langlois MR, Taes YE, De Buyzere ML, Verstraete 
AG. Automated Flow Cytometric Analysis of Cerebrospinal Fluid. Clin Chem 
2001;47:556-60. 
34.  Aps JKM, Van den Maagdenberg K, Delanghe JR, Martens LC. Flow cytometry as a 
new method to quantify the cellular content of human saliva and its relation to 
gingivitis. Clinica Chimica Acta 2002;321:35-41. 
35.  Muylaert, A., Schoonjans, F., Bernard, D., Comhaire, F., and Delanghe, J. Analysis 
of semen samples on the Sysmex UF-100. Acta Clinica Belgica 55, 44. 2000.  
36.  Delanghe JR, Kouri TT, Huber AR, Hannemann-Pohl K, Guder WG, Lun A et al. 
The role of automated urine particle flow cytometry in clinical practice. Clin Chim 
Acta 2000;301:1-18. 
37.  Delanghe, J., Langlois, Michel R., Wuyts, Birgitte, and De Buyzere, Marc L. 
Performance of urinary flow cytometry in predicting outcome of urine cultures. J 
Clin Microbiol 40[6], 2314-2315. 2002.  
38.  Kouri T, Fogazzi G, Gant V, Hallander H, Hofmann W, Guder WG. ECLM. 
European Urinalysis Guidelines. Scand J Clin Lab Invest 2000;60 (Suppl 231):1-96. 
  
39.  Penders, J., Fiers, T., Dhondt, A. M., Claeys, G., and Delanghe, J. R. Automated flow 
cytometry analysis of peritoneal dialysis fluid. Nephrol Dial Transplant 19, 463-468. 
2004.  
40.  Penders J, Fiers T, Delanghe JR. Quantitative evaluation of urinalysis test strips. Clin 
Chem 2002;48:2236-41. 
41.  Penders, J., Fiers, T., Giri, Mimi, Wuyts, Birgitte, Ysewyn, Larissa, and Delanghe, 
Joris R. Quantitative measurement of ketone bodies in urine using reflectometry. Clin 
Chem Lab Med 43[7], 724-729. 2005.  
42.  Everaert K, Hoebeke P, Delanghe J. A review on urinary proteins in outflow disease 
of the upper urinary tract. Clinica Chimica Acta 2000;297:183-9. 
43.  Penders J, Delanghe JR. Alpha 1-microglobulin: clinical laboratory aspects and 
applications. Clinica Chimica Acta 2004;346:107-18. 
44.  Ivandic M, Hofmann W, Guder WG. The use of knowledge-based systems to 
improve medical knowledge about urine analysis. Clinica Chimica Acta 
2000;297:251-60. 
45.  Levey, A. S., Eckardt, K. U., Tsukamoto, Y., Levin, A., Coresh, J., Rossert, J., 
Zeeuw, D., Hostetter, T. H., Lameire, N., and Eknoyan, G. Definition and 
classification of chronic kidney disease: a position statement from Kidney Disease: 
Improving Global Outcomes (KDIGO). Kidney International 67[6], 2089-2100. 
2005.  
46.  Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M. 
Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and 
Management of Diabetes Mellitus. Clinical Chemistry 2002;48:436-72. 
47.  Deferrari, G., Repetto, M., Calvi, C., Ciabattoni, M., Rossi, C., and Robaudo, C. 
Diabetic nephropathy: from micro- to macroalbuminuria. Nephrol Dial Transplant 13 
(Suppl 8), 11-15. 1998.  
48.  Rodico, J. Does antihypertensive therapy protect the kidney in essential 
hypertension? J Hypertension Suppl 14, S69-75. 1996.  
49.  Mogenson, C. Microalbuminuria predicts clinical proteinuria and early mortality in 
maturity-onset diabetes. The New England Journal of Medicine 310, 356-360. 1984.  
50.  Kutter D. The urine test strip of the future. Clinica Chimica Acta 2000;297:297-304. 
51.  Pugia MJ, Sommer RG, Kuo HH, Corey PF, Gopual DL, Lott JA. Near-patient 
testing for infection using urinalysis and immuno-chromatography strips. Clin Chem 
Lab Med 2004;42:340-6. 
  
52.  Hoque MO, Topaloglu O, Begum S, Henrique R, Rosenbaum E, Van Criekinge W et 
al. Quantitative Methylation-Specific Polymerase Chain Reaction Gene Patterns in 
Urine Sediment Distinguish Prostate Cancer Patients From Control Subjects. J Clin 
Oncol 2005;23:6569-75. 
  
 
 
  
SAMENVATTING 
 
Deze thesis handelt over de beschikbare state-of-the-art geautomatiseerde urine-analyse 
technieken in een routine laboratorium en bekijkt de mogelijkheden om het gebruik ervan 
in een klinische en laboratoriumpraktijk uit te breiden en de diagnostische mogelijkheden 
te verbeteren. 
In de huidige praktijk worden resultaten van urine test strips gerapporteerd als semi-
kwantitatieve data hoewel de oorspronkelijke aflezing een kwantitatief resultaat is onder de 
vorm van % reflectantie. We bekeken de prestatie van de testvelden als ze kwantitatief 
werden gerapporteerd en konden besluiten dat de data van de hemoglobine en 
leukocytenesterase testvelden complementair waren aan de flow cytometrische resultaten 
voor deze parameters terwijl de glucose en albumine velden vergelijkbare resultaten gaven 
met de routine chemische methoden. Dit zou een belangrijk hulpmiddel kunnen zijn in de 
screening naar microalbuminurie en zou de huidige expertsystemen kunnen aanvullen die 
nu gebruikt worden om bepaalde tekortkomingen in de flow cytometrie te compenseren. 
Met een gewone test strip is het enige keton dat men kan meten acetoacetaat. We bekeken 
de mogelijkheid om ook de andere ketonen (aceton, 3-hydroxyboterzuur) te meten in urine. 
We konden, mede door een speciale staalvoorbereiding, alle drie de ketonen meten en 
vonden een lage nierdrempel voor deze analyten. Dit levert een methode op die een 
eenvoudige en snelle screening toelaat om ketonen te meten in urine van diabetespatiënten 
voornamelijk in een spoedgevallensetting. Dit zou kunnen bijdragen tot een completer 
beeld van de patiënt die naar een diabetisch coma neigt. 
Flow cytometrie is een wijdverspreide techniek in de urine analyse en wij konden aantonen 
dat het ook bruikbaar is als snelle screeningsmethode voor leukocyten in CAPD-vocht. De 
gevoeligheid van het ‘bacterie’-kanaal in het voorspellen van positieve culturen was beter 
dan deze van de conventionele Gramkleuring. Ook de aanwezigheid van gisten in het vocht 
kan onderzocht worden. 
Alpha 1-microglobuline bleek, tijdens het opstellen van een review, een van de meest 
bruikbare parameters in de diagnostiek van renale en urologische aandoeningen. Door het 
integreren van meetgegevens bekomen door test strip analyse, flow cytometrie en het 
meten van verschillende eiwitten konden we enkele formules voorstellen die kunnen 
dienen in de diagnostiek van deze aandoeningen. Door het integreren in expertsystemen 
zou er aan clinici extra diagnostische informatie geboden kunnen worden. 
  
 
  
SUMMARY 
 
This thesis explores the possibilities of the available state-of-the-art automated urinalysis 
techniques in a routine clinical laboratory setting to expand their use in clinical and 
laboratory practice and to improve the diagnostic possibilities by combining the 
information obtained by these individual techniques. 
While the original reading data are quantitative reflectance values, urine test strip reading 
is usually reported as semi-quantitative, ordinal data. The performance and possible 
advantage of reporting quantitative data was investigated and quantitative hemoglobin and 
leukocyte esterase reflectance data proved to be complementary with flow cytometric 
results while glucose and albumin results were complementary to routine chemistry 
methods. This opens possibilities to use this technique as a screening tool in detecting 
microalbuminuria and to improve existing expert systems that try to overcome certain 
pitfalls of urine flow cytometry. 
Furthermore, urine test strips can only measure acetoacetate. We explored the possibility of 
measuring all ketone bodies (acetone, acetoacetate, 3-hydroxybutyrate) in urine with these 
routine test strips and found that renal threshold levels were low enough to allow 
quantitative ketone reflectance data to provide a simple and fast analysis, offering 
affordable screening for the detection of ketone body production in diabetes, especially in 
emergency settings. This might add valuable information in this setting, to gain a more 
complete picture of the patient status. 
Flow cytometry is also a widely accepted technique for urinalysis and we proved it to offer 
a rapid and reliable leukocyte count in CAPD-fluid investigation. Sensitivity of the 
‘bacterial’ channel count in predicting positive culture exceeded the sensitivity of 
conventional Gram stain while additional semi-quantitative information is provided 
regarding the presence of yeasts. 
Specific proteins are used in renal and urological diagnostic strategies and while reviewing 
the literature about alpha 1-microglobulin, it proved to be one of the most useful analytes 
in this setting. By integrating information from test strip reading, flow cytometry and 
proteins, we proposed some ratios that may be helpful in classifying renal and urological 
conditions. Possible integration in computer-based knowledge systems may offer valuable 
information for clinicians. 
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